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           Manganese (Mn) exposure is a growing public health concern as new evidence 
continues to show that high level exposure to this essential metal is toxic. Chiefly toxic to 
the central nervous system, it produces signs and symptoms resembling, but not identical 
to idiopathic Parkinson’s disease. The hypothesis tested in this dissertation is that Mn 
accumulation in body tissues produces subclinical changes in the central nervous system 
altering neuronal repair mechanisms and leading to neurodegenerative damage. The 
studies in this dissertation evaluated the extent of these changes in the central nervous 
system. Changes in the toxicokinetic properties of Mn in bone affecting the parameters of 
accumulation, distribution, and elimination were also identified. Importantly, the half-life 
of Mn in bone was estimated to be approximately 8.6 years in humans, a finding which 
will be essential in developing a biomonitoring system for Mn exposure. Significant 
accumulation of Mn in brain and body tissues was observed along with significant metal 




neurochemistry, and as a consequence, impaired motor function was observed. The 
subventricular zone (SVZ), one of two neurogenic niches in the adult brain, had the 
largest magnitude of change. Therefore, effects of Mn exposure on cell proliferation and 
differentiation in this region were investigated further. The processes involved in adult 
neurogenesis were significantly altered following Mn exposure, particularly with regard 
to cell proliferation. The full extent of the consequences resulting from Mn exposure in 
the pathology of neurodegenerative disease remains unknown, but the results of these 
studies demonstrate that although Mn exposure undoubtedly leads to several changes 
observed early in neurodegenerative disease pathology, no overt neurodegeneration was 
observed. The results of this work will help researchers studying the effect of metal 
exposure on adult neurogenesis and will also help researchers studying neurodegenerative 




CHAPTER 1: INTRODUCTION AND BACKGROUND 
 
1.1 Abstract 
Exposure to manganese (Mn) causes clinical signs and symptoms resembling, but 
not identical to, Parkinson’s disease. Since the last review on this subject by this group in 
2004, the past decade has been a thriving period in the history of Mn research. This 
chapter provides a comprehensive review on new knowledge gained in the Mn research 
field. Emerging data suggest that beyond traditionally recognized occupational 
manganism, Mn exposures and the ensuing toxicities occur in a variety of environmental 
settings, nutritional sources, contaminated foods, infant formulas, and water, soil and air 
with natural or man-made contaminations. Upon fast-absorption into the body via oral 
and inhalation exposures, Mn has a relatively short half-life in blood, yet fairly long half-
lives in tissues. Recent data suggest Mn accumulates substantially in bone, with a half-
life of about 8-9 years expected in human bones. Mn toxicity has been associated with 
dopaminergic dysfunction by recent neurochemical analyses and synchrotron X-ray 
fluorescence imaging studies. Evidence from humans indicates that individual factors 
such as age, gender, ethnicity, genetics, and pre-existing medical conditions can have 
profound impacts on Mn toxicities. In addition to body fluid-based biomarkers, other 




noninvasive measurement of Mn in bone, and functional alteration assessments. The 
information provided in this chapter is intended to establish the importance of this 
research. More specific background for research presented in each chapter will be 
provided in the introduction sections of respective chapters. 
 
1.2 Introduction 
Manganese (Mn) is the 12th most abundant element on the earth (Nadaska et al., 
2012). As a transition metal, Mn exists in more than five valence states, with a majority 
as Mn2+ or Mn3+ (Aschner et al., 1999). In the environment, it is found mainly in its 
oxidized chemical forms, as MnO2 or Mn3O4 (Post, 1999). Mn is essential to human 
health, acting as a co-factor in the active centers of various enzymes, and is required for 
normal development, maintenance of nerve and immune cell functions, and regulation of 
blood sugar and vitamins, among other functions (Aschner et al., 2007; Crossgrove and 
Zheng, 2004; Guilarte, 2010). Overexposure to this metal, however, causes toxicity to 
many organ systems and across different life stages. Clinically, this toxicity is termed 
manganism.  
In 2004, this group summarized the impact of Mn exposure on general human 
health (Crossgrove and Zheng, 2004). At the time, a majority of evidence on Mn 
intoxication came from occupational settings, because of high exposure levels. Over the 
past decade, much progress has been made in the Mn research field, from toxicokinetics 
to exposure assessment and from the mode of action to clinical therapeutic intervention. 




exposure, with air Mn concentrations at or below occupational standards can also be 
detrimental. Neurochemical, neurobehavioral, and neuroendocrine changes may occur 
before structural damage occurs, and are linked to pathogenic conditions (Alessio et al., 
1989; Cowan et al., 2009a,b; Dydak et al., 2011; Lucchini and Zimmerman, 2009; Mutti 
et al, 1996). In addition to the exposure level and duration, there are other unique factors, 
such as age, gender, ethnicity, genetics, location, and pre-existing medical conditions that 
may contribute to Mn toxicity.  
This chapter seeks to provide a comprehensive review of the new insights into 
environmental Mn exposure gained in the last decade. The current understanding of Mn 
toxicokinetics and its distribution in brain by using advanced synchrotron X-ray 
fluorescence imaging technique will be first introduced. The advantage and disadvantage 
of using bone Mn levels as a potential indicator for Mn body burden will be addressed. 
This will be followed by a general review of the updated knowledge on Mn systemic 
toxicities including effects on brain, liver, and the cardiovascular system. Finally, 
comments and recommendations will be made with regard to the diagnosis of Mn 
intoxication and clinical intervention.  
 
1.3 Absorption, Distribution, and Elimination 
The highest concentrations of Mn are present in bone, liver, kidney, pancreas, 
adrenal and pituitary glands (Rahil-Khazen et al., 2002). The normal concentration of Mn 
in human tissues is 1 mg/kg in bone (Liu et al., 2014), 1.04 mg/kg in pancreas, and 0.98 
mg/kg in kidney cortex (Rahil-Khazen et al., 2002).  The normal blood Mn 




the general Chinese population suggests that women have a higher blood Mn level than 
men (~28.6%) (Zhang et al., 2015). Mn is transported and regulated by several 
























Table 1. Proteins Involved in Maintaining Mn Homeostasis. Proteins required for  
regulating Mn are shown in conjunction with the particular species bound and the  
corresponding function.  
 





Divalent metal transporter 
(DMT1/SLC11A2)  Mn2+ Mn uptake  Au et al., 2008 
Transferrin (Tf) Mn3+ Mn uptake Aschner and Gannon, 1994 
Tf Receptor (TfR) Mn3+ Mn uptake  Baker et al., 2015 
Citrate Mn2+ 
Mn transport in blood brain 
barrier Crossgrove et al., 2003 
ZIP8 (SLC39A8) Mn2+ Mn uptake He et al., 2006 
ZIP14 (SLC39A14) Mn2+ Mn uptake Fujishiro et al., 2012 
Voltage regulated calcium 
channels Mn2+ Mn uptake Lucaciu et al., 1997 
Ionotropic glutamate receptor 
calcium channels ? Mn uptake Kannurpatti et al., 2000 
Store-operated calcium 
channels Mn2+ Mn uptake 
Crossgrove and Yokel, 
2005 
SLC30A10 ? Mn efflux DeWitt et al., 2013 
Ferroportin (SLC40A1) Mn2+ Mn efflux 
Madejczyk and Ballatori, 
2012 
Metallothionein ? storage protein Kobayashi et al., 2007 
Iron-responsive element-
binding protein (IRP1) Mn2+ 
Mn can replace the 4th Fe in 
the 4Fe-4S active center. Wang et al., 2006 
Ceruloplasmin Mn2+ 
potentially oxidizes Mn(II) to 
Mn(III) Gibbons et al., 1976 
superoxide dismutase   
oscillates between Mn(II) and 
Mn(III) species Sheng et al., 2012 












1.3.1 Chemical Species of Mn in Body Fluids 
In the human body, Mn exists primarily in two oxidized states, i.e., Mn2+ and 
Mn3+. Mn2+ species in the blood are bound to high molecular mass fractions, such as 
albumin and β-globulin as hydrated ions, and also in complexes with bicarbonate, citrate, 
and other low molecular mass species (Harris and Chen, 1994; Reaney et al., 2002). 
Nearly 100% of Mn3+ species are bound to transferrin (Tf), to form a more stable 
complex (Michalke and Fernsebner, 2014). Mn molecules in tissues such as liver, kidney, 
pancreas, bone, and brain exist primarily as Mn2+ (Crossgrove and Zheng, 2004). 
In the cerebrospinal fluid (CSF), Mn2+ ions are bound to low molecular weight 
compounds, such as Mn-citrate (Michalke and Fernsebner, 2014). This form is thus 
thought to be transported by a citrate transporter (Yokel, 2009). More evidence, however, 
suggests that Mn2+ species are transported mainly by the divalent metal transporter-1 
(DMT1) as the primary influx route to brain, although the other transporting proteins 
such as ZIP8 are suggested to mediate Mn transport into brain (Aschner et al., 2007; 
Chua and Morgan, 1997). Evidence in literature has also suggested that Mn2+ can enter 
the brain by store-operated calcium channels; but the extent of this route is much less 
than that of transporter-mediated transports (Yokel, 2009). The other Mn species entering 
the brain is Mn3+, which is complexed with transferrin and via the transferrin receptor 
(TfR)-mediated process (Zheng, 2005, Table 1).  
 
1.3.2 Absorption 
The main route of Mn absorption is through the gastrointestinal tract; but the 




The intravenous injection of illegal narcotics containing Mn has recently provided a third 
route of exposure (Sikk et al., 2011). 
Inhalation exposure to airborne Mn is common among welders and smelters 
(Jiang et al., 2006; Korczynski, 2000; Leavens et al., 2007). Inhaled Mn can by-pass the 
liver to enter the blood stream; from there it can enter the brain via the olfactory tract 
bypassing the blood brain barrier (Lucchini et al., 2012; Zoni et al., 2012). Studies in rats 
demonstrate that Mn is rapidly transported along the evolutionarily conserved olfactory 
pathway and is present within the olfactory bulb 8-48 hours after exposure. It is believed 
that the trigeminal nerve may also play a role in delivering Mn from the nasal cavity to 
the brain (Kanayama et al., 2005; Leavens et al, 2007; Zoni et al., 2012).  
Oral exposure is another common route of exposure. Mn is required in small 
quantities obtained through dietary intake. The average daily intake for many Western 
diets is between 2.3 and 8.8 mg (EPA, IRIS); but this can be much higher. Consumption 
of food or water contaminated with high levels of Mn has toxic consequences (Kondakis 
et al., 1989). For example, the water supply in Bangladesh is contaminated with Mn up to 
2.0 mg/L (Frisbie et al., 2002), which is 4-fold higher than the WHO standard for 
drinking water of 400 µg/L (Khan et al., 2012). Studies among school children suggest 
that increased levels of Mn in the drinking water in Bangladesh area are inversely 
associated with students’ achievement scores in mathematics (Khan et al., 2013). High 
levels of Mn in drinking water in Canada have been found to lead to significantly higher 
levels of Mn in hair samples in school-age children. The increased hair Mn 
concentrations are significantly associated with increased hyperactive behaviors 




decrease in IQ points (Bouchard et al., 2011). In Italy, school-age children living near a 
ferroalloy plant have been found to have significant impairment of motor coordination, 
hand dexterity, and odor identification after exposure to excess levels of Mn in soils 
(Lucchini et al., 2012). It is alarming that the high Mn concentration in drinking water is 
not solely a public health issue unique to developing countries; approximately 5.2% of 
the 2,167 wells surveyed across the United States exceeded the health benchmark of 300 
µg/L (DeSimone et al., 2009). 
Another potential source of oral exposure is from consuming milk- or soy- based 
infant formulas, which contain high levels of Mn. The FDA sets a minimum nutritional 
requirement of 5 μg/100 kcal for the amount of Mn infant formulas must contain; yet 
there is no maximum established. According to the Institute of Medicine’s 
recommendation, infants can consume about 3 µg Mn/day for 0-6 months. Infants can 
drink up to a liter of formula a day. When formula is prepared according to the 
manufacturer’s instructions, infants could consume from 32-51 µg of Mn per day, far 
exceeding the aforementioned recommendation. Soy-based formulas contain more Mn 
than cow-based formulas, and both contain much more Mn than does human breast milk 
(Tran et al., 2002). Since only a small percentage of Mn is eliminated in human 
breastmilk and because breastfed babies consume smaller volumes of milk than do bottle-
fed babies at each feeding (Stastny et al., 1984), feeding breastmilk is considered much 
safer than feeding formulas to infants. It is also known that the concentrations of Mn in a 
mother’s milk decrease as lactation progresses. Laboratory testing has shown that babies 
who drink formulas had higher concentrations of Mn in hair samples than those who were 




suggested to be associated with the risk of developing the attention deficit hyperactivity 
disorder (Aschner and Aschner, 2005).  
Recently, cases of Mn-induced Parkinsonism have been reported among 
intravenous ephedrone abusers in Estonia, Turkey, Eastern Europe, the Baltic States and 
Canada (Tuschl et al., 2013; Zheng, 2005). Mn is added to the drug cocktail as the 
oxidizing agent potassium permanganate; the final Mn concentration can be as high as 
0.6 g/L. Multiple injections per day can result in doses ranging from 60-180 mg/day by 
intravenous administration. This amount far exceeds the 0.1 mg Mn/day recommended as 
an intravenous supplement. Continued uses can lead to elevated Mn concentrations in 
blood and urine, and patients have signs and symptoms such as impaired speech, 
cockwalk, bradykinesia and ataxia (Sikk et al., 2011) Even after cessation of ephedrone 




Once Mn enters systemic circulation from either the small intestine or lung, it 
mainly accumulates in liver (1.2-1.3 mg/kg), brain (0.15-0.46 mg/kg) and bone (1 mg/kg 
up to 43%) (Krebs et al., 2014; Liu et al., 2014; Rahil-Khazen et al., 2002; Subramanian 
and Meranger, 1985). Mn is detectable in the CSF before it is detectable in the brain 
parenchyma, suggesting that it is transported through the choroid plexus (Schmitt et al., 
2011).  
The brain is the target organ of Mn toxicity. In human subjects exposed to Mn in 




globus pallidus than in other brain structures (Dydak et al., 2011; Jiang et al., 207). Rapid 
advancement in synchrotron X-ray fluorescence (XRF) imaging technique has made it 
possible to illustrate the Mn distribution pattern in the brain. In rat brains, Mn 
accumulates with the highest concentration in the globus pallidus, followed by substantia 
nigra pars compacta, thalamus, caudate putamen, axon bundles, and cortex (Robison et 
al., 2012). While the hippocampus does not contain more Mn than other brain regions in 
control animals, Mn exposure in fact increases hippocampal Mn to the same level as 
those in substantia nigra pars compacta and thalamus. Thus, it appears that the 
hippocampus is susceptible to Mn toxicity. Moreover, the XRF data show that Mn tends 
to accumulate in brain regions that also have a high iron (Fe) concentration (Robison et 
al., 2013).  
Mn concentrations are thought to be greater in astrocytes than in neurons (Tuschl 
et al., 2013). However, the XRF data from single cells show a diffuse Mn distribution 
pattern within cells of hippocampus CA3, which are likely neurons. Since only 30% of 
astrocytes are saturated after Mn exposure, it seems unlikely that astrocytes serve as the 
primary target of Mn accumulation in the rodent model (Robison et al., 2013).  
In addition to brain and liver, Mn accumulates extensively in human bone under 
normal physiological conditions (Pejovic-Milic et al., 2009). By examining the human 
bone collected during autopsy, it is estimated that bone contains about 40% of the total 
body burden of Mn (Schroeder et al., 1966). Our recent study in rats has shown that after 
subchronic oral exposure to Mn, Mn accumulates in femur, tibia, humerus, and parietal 
bone with accumulation reaching steady state concentrations after 6 weeks of dose 




Mn is intracellularly distributed in red blood cells due to the presence of 
transferrin receptor (TfR) and divalent metal transporter-1 (DMT1) in this cell type 
(Crossgrove and Zheng, 2004; Jiang et al., 2007). Inside the cell, Mn acts on 
mitochondrial complex I and disrupts energy production (Chen et al., 2001; Jiang and 
Zheng, 2005; Zheng et al., 1998). But mitochondria may not be the major intracellular 
organelles where Mn ions accumulate. Morello and colleagues (2008) used electron 
spectroscopy imaging and demonstrated that the highest concentrations of Mn were 
present in the heterochromatin and the nucleolus, followed by a lower concentration of 
Mn in the cytoplasm, with the lowest levels in mitochondria. After chronic Mn exposure, 
the highest levels of Mn were observed in the mitochondria (Morello et al., 2008).   
In a comparative in vitro study utilizing choroidal epithelial Z310 cells, rat brain 
endothelial RBE4 cells, dopaminergic N27 and PC12 cell lines, cells were fractionated to 
separate nuclei and mitochondria. After Mn exposure, the highest levels of accumulation 
were found in the PC12 and N27 neuronal cell types compared with the non-neuronal 
brain barrier Z310 and RBE4 cell types. Most Mn was present within the nuclei, which 
was true for all four cell lines; only limited accumulation was observed in mitochondria 
(<0.5%) and microsomes (<2.5%) (Kalia et al., 2008). Nonetheless, the profound Mn 
toxicity on mitochondrial function should not be underestimated.   
 
1.3.4 Elimination 
The primary route of Mn elimination is via the fecal hepatobiliary excretion with 
limited urinary excretion (Klaassen, 1976). Some Mn-containing molecules such as Mn-




(Bellusci et al., 2014; Marchal et al., 1993; Zhu et al., 2014). Mn is also eliminated in 
milk as mentioned above. However, this route of elimination does not constitute a major 
route of Mn excretion. Similarly, very low levels of Mn are excreted in sweat 
(Omokhodion and Howard, 1994). 
In the brain parenchyma, Mn rapidly accumulates in brain structures such as the 
superior and inferior colliculi, amygdala, stria terminalis, hippocampus, and globus 
pallidus. The half-lives of Mn in these tissues are about 5-7 days, with the longest 
retention in the periaqueductal gray, amygdala, and entorhinal cortex (Grunecker et al., 
2013). The elimination rate from brain tissue is expected to be slower than from either 
liver or kidney. In the rat, the half-lives of 16 brain regions are between 52 and 74 days 
(Crossgrove and Zheng, 2004). 
 In a study described in Chapter 2, we administered Mn by oral gavage at 50 
mg/kg for 10 weeks. It was interesting to observe that by the fourth week of dose 
administration, Mn in blood reached the steady-state concentration, which was 
maintained for the duration of the study. Mn concentrations in the CSF, however, 
continued to increase even at the 8th week. It is possible that a slow elimination of Mn 
from the CSF may contribute to the high level of Mn in the brain (O’Neal et al., 2014a). 
It is also possible that a redistribution of Mn from the bone compartment to the central 
nervous system may account, at least partially, for the high level of Mn in the CSF. By 
studying the elimination rate constant and half-lives, our data revealed that the half-lives 
of Mn in various rat bones were between 77 and 690 days with an average of 143 days 
for the whole skeleton (O’Neal et al., 2014a). A comparative study between human and 




(Sengupta, 2011). By using this figure, the range of Mn half-lives in the rat skeleton is 
estimated approximately 4.6 – 41.3 years in humans with an average half-life of 8.6 years 
for humans (O’Neal et al., 2014a).  
 
1.4 Human Exposure to Mn 
The primary source of clinically identified Mn intoxication is due to occupational 
exposure. Neurotoxicity due to inhalation exposure to airborne Mn has been reported in 
miners in Mn dioxide mines (Couper, 1837), workers in dry-cell battery factories (Keen 
and Lönnerdal, 1995), smelters (Cowan et al., 2009a,b; Huang et al., 1989; Jiang et al., 
2006; Jiang et al., 2007), steel manufacturing workers or welders (Bowler et al., 2011; Lu 
et al., 2005; Ono et al., 2002; Racette et al., 2012; Wang et al., 1989). Our own studies on 
3,200 welders in 142 factories in the metropolitan area of Beijing reveal a significant 
correlation between airborne Mn level and manganism among welders with an estimated 
exposure dosages (calculated by the weight of welding rods) of 5-20 kg (containing 0.3-
6% Mn) per working day per person (Crossgrove and Zheng, 2004; Want et al., 1998). 
There are many environmental sources of Mn, which include eroded rocks, soils 
and decomposed plants. Human activities expose individuals to additional sources 
containing Mn, including the fungicides, Maneb and Mancozeb, medical imaging 
contrast agents, and water purification agents. Additionally, several countries including 
the United States, Canada, Argentina, Australia, Bulgaria, France, Russia, New Zealand, 
China, and the European Union have approved use of the fuel additive 
methylcyclopentadienyl manganese tricarbonyl (MMT)  (Michalke and Fernsebner, 




phosphates, sulphates and oxides into the air, especially where there is high traffic 
density releasing particles within the respirable size range (Frumkin and Solomon, 1997; 
Nadaska et al., 2012). Mn-containing emissions contaminate soil, dust and plants near 
roadways, which introduces additional Mn to the environment (Lytle et al., 1995). Recent 
projections of MMT use indicates the average person’s Mn absorption may increase by 
several percent. It should be noted that this is an estimated average level of exposure; 
therefore some people may be exposed more substantially than others (Frumkin and 
Solomon, 1997). 
Ultimately, Mn from these various sources ends up in the water supply. As Mn 
filters down through the soil, it is reduced to the more soluble Mn2+ form where it can 
easily make its way into ground and surface waters. Ground water has the highest 
concentration of Mn; but surface water and water near mining operations contain high 
levels of Mn as well (Nadaska et al., 2012).  
 
1.5 Manganese-Induced Toxicities 
Mn can be stored in organs such as the liver and bone with limited local effects, 
but Mn targets multiple organ systems with severe consequences including the 
cardiovascular, reproductive, and respiratory; the main target of Mn toxicity is the central 
nervous system.    
 
1.5.1 Mn-Induced Neurotoxicity 
Cumulative evidence has established that Mn exposure induces signs and 




al., 2001; Racette et al., 2005; Rutchik et al., 2012a,b; Tuschl et al., 2013). Early 
symptoms of Mn toxicity include cognitive deficits and psychiatric disturbances, 
followed by motor symptoms including rigidity, postural impairment, and tremors 
(Guilarte and Gonzales, 2015). A study on six manganism patients who were 
occupationally exposed to Mn as welders or smelters in Guangxi, China suggested that 
Mn exposure led to clinical manifestations of Parkinsonian syndromes with considerable 
variations. One patient who had a classic presynaptic syndrome and responded to L-
DOPA was clearly Mn-intoxicated. Moreover, a case with 25-year Mn exposure showed 
a syndrome of Parkinsonism at an early age with magnetic resonance imaging (MRI) 
abnormalities bilaterally in the globus pallidus (Rutchik et al., 2012a,b). Thus, these 
observations support an overlap in syndromes between Mn-induced movement disorder 
and Parkinson’s disease (Racette et al., 2001; Racette et al., 2005; Rutchik et al. 2012a,b). 
While the linkage between manganism and Parkinson’s disease is noteworthy, 
animal studies suggest that dopaminergic neurons in the substantia nigra and their 
terminals in the striatum, which are selectively lesioned in Parkinson’s disease, remain 
intact after Mn intoxication (Guilarte, 2010). Additionally, following Mn toxicity, 
patients are typically unresponsive to levodopa, the dopamine precursor (Guilarte and 
Gonzales, 2015). Thus, changes in neurotransmission, rather than a massive dopamine 
neuronal cell loss, likely underlie behavioral observations.  
Reports of Mn exposure altering neurotransmitter and metabolite levels have been 
published in literature (Gwiazda et al., 2007; Racette et al., 2012a). In Chapter 3, we 
investigated changes in dopamine, dopamine metabolites, including 3,4-




in rat brain after Mn exposure. Our data showed a significantly increased dopamine level 
in the striatum; this increase was accompanied by increased levels of DOPAC and HVA 
in the same region. In agreement with our report, Vorhees and colleagues (2015) recently 
showed that Mn exposure increased striatal dopamine and HVA concentrations compared 
to controls. They also observed an increased norepinephrine in the striatum and increased 
dopamine, norepinephrine, and serotonin levels in the hippocampus. By utilizing various 
ages of animals, these investigators reported that Mn exposure altered monoamines as a 
function of age (Vorhees et al., 2015).  
In a human study utilizing magnetic resonance imaging and spectroscopy (MRI/S) 
to investigate changes in neurochemistry of smelting workers, increases in GABA and 
decreases in myo-inositol were seen in the thalamus. Changes in thalamic GABA were 
associated with reduced fine motor performance as assessed by the Purdue pegboard test 
(Long et al., 2014). 
Recent investigation of Mn neurotoxicity has also extended to the field of adult 
neurogenesis, which takes place in two critical niche areas in brain, i.e., the 
subventricular zone (SVZ) and the subgranular zone (SGZ). Application of the 
synchrotron XRF imaging technique to study brain distribution of copper (Cu) and Fe 
with or without Mn exposure has led to the unexpected discovery that Cu concentrations 
in the SVZ are considerably higher than in any other brain regions (Pushkar et al., 2013). 
Further in vivo studies revealed that subchronic Mn exposure in rats greatly increased the 
cell proliferation in the SVZ and the associated RMS, but significantly reduced the Cu 
levels in the SVZ (Fu et al., 2015). These observations raised the interesting question as 




intracellular storage and trafficking may affect Cu homeostasis and ultimately alter 
normal neuronal repair processes, which may contribute to the non-motor symptoms 
characteristic of Mn-induced Parkinsonian disorder. The research presented in Chapter 4 
was designed to study the effect of Mn toxicity on adult neurogenesis following 
intranasal exposure. 
Kikuchihara and colleagues (2015) further confirmed that oral Mn exposure 
resulted in reduced numbers of local Pvalb+ GABAergic interneurons in the other 
neurogenic niche, the SGZ of the dentate gyrus in the HP of mice (Kikuchihara et al., 
2015). Similar to the data published by our group, Kikuchihara’s group also observed a 
reduced Cu level in the subgranular zone after Mn exposure, although differences in 
animal species, exposure route, and duration between these two studies are evident. Since 
Mn exposure results in reduced Cu levels in both neurogenic niches, these two 
independent studies may suggest a similar molecular mechanism underlying Mn 
neuropathology. 
 
1.5.2 Mn-Induced Cardiovascular Toxicity 
Despite a lack of epidemiological evidence, animal and human evidences support 
the view that Mn exposure significantly alters cardiovascular function. Intravenous 
injection of Mn at high dose (5-10 mg Mn/kg) caused a decreased heart rate and blood 
pressure and increased P-R and QRS intervals (Charash et al., 1982). In perfused rat 
hearts, an MRI contrast agent Mn-DPDP had similar, but reduced effects on cardiac 
function as compared with Mn2+ (Vander et al., 1997). Limited data from human 




opposed to the decreased blood pressure and heart rate observed in animal studies, 
smelters showed significantly faster heart rates than control subjects. Additionally, while 
animal studies showed increased P-R intervals, the reverse was true for the smelters, 
although the QRS and T waves were wider and elevated in both male and female smelters 
compared to controls (Jiang and Zheng, 2005).  
Overexposure to the MRI enhancer Mn-DPDP causes flushed face and the head 
and ears feeling hot. Postural hypotension has also been observed in Mn-DPDP-
overdosed patients (Jiang and Zheng, 2005). Even when cardiac function is not 
significantly altered, the mean diastolic blood pressure can be significantly lower, while 
and diastolic hypotension can be significantly higher, in Mn-exposed workers as 
compared to control subjects. Workers with the highest level of exposure to Mn exhibit 
the lowest systolic blood pressure (Jiang and Zheng, 2005).  
Despite differences in levels of exposure between human and animal studies, it 
appears that Mn exposure inhibits myocardial contraction, dilates blood vessels and 
induces hypotension, suggesting that Mn exposure has a significant effect on cardiac 
function. The exact mechanism of cardiac toxicity remains unknown; it has been shown 
that Mn has a direct effect on mitochondrial function resulting in a reduced myocardial 
contraction, and causes vasodilation, leading to a decreased blood pressure following 
acute exposure (Jiang and Zheng, 2005). However, the research evidence on whether and 
how chronic low level Mn exposure causes cardiovascular toxicities from both human 






1.5.3 Mn Exposure and Infant Mortality 
Increased Mn levels in water sources have been linked to increased infant 
mortality. An analysis of groundwater concentrations in North Carolina reveals that 
infant mortality increases by a factor of 2 per 1,000 live births for every log increase in 
groundwater Mn concentration (Spangler and Spangler, 2009). Hafeman et al. (2007) also 
report an increased mortality in the first year of life in infants in Bangladesh exposed to 
Mn concentrations at or above the WHO’s standard of 400 µg Mn/L compared to 
unexposed infants (Hafeman et al., 2007). 
 
1.5.4 Mn Toxicity and Liver Function 
Since the original report by Klaassen in 1976 describing the hepatobiliary 
excretion of Mn from the liver (Klaassen, 1976) not much work has been done to 
describe Mn-induced hepatotoxicity. The liver is a known storage organ for Mn; the 
highest Mn uptake occurs in the liver, only second to brain uptake (Chua and Morgan, 
1997). Hepatic Mn accumulation in mice intravenously injected with Mn nanoparticles 
persisted significantly longer than other highly perfused tissues such as kidney and 
spleen; however, no histopathological damage was observed (Bellusci et al., 2014). 
Hepatobiliary excretion of Mn represents a primary route of Mn clearance from 
the body, accounting for 80% of Mn elimination. Thus, severe liver damage, owing to 
various chronic liver diseases, can result in an excessive accumulation of Mn in brain 
with ensuing signs and symptoms clinically called Mn hepatic encephalopathy (Long et 
al., 2009). With weakened liver function, there is also an increased risk of 




with chronic hepatic encephalopathy, liver transplant has proven to be effective in 
reducing brain Mn concentrations. When patients were re-examined 5 months after 
transplant, the T1-weighted MRI signals in the basal ganglia were absent (Long et al., 
2009). These data suggest that the normal liver function is essential to maintain 
homeostasis of Mn in the body, including the central nervous system (CNS).  
 
1.5.5 Mn Toxicity and Individual Susceptibility 
There are many factors that may predispose one individual to Mn toxicity over 
another. These individual factors include age, gender, ethnicity, genetics, and pre-existing 
medical conditions, such as chronic liver disease. 
Age is a common factor which may influence an individual’s susceptibility to Mn 
toxicity. Very young animals as well as humans have increased intestinal Mn absorption 
(Vorhees et al., 2015) and also have increased accumulations of Mn in the CNS (Cahill et 
al., 1980), due to increased permeability of neuronal barriers to Mn (Michalke and 
Fernsebner, 2014).  The young also have a reduced biliary excretion capacity (Aschner 
and Aschner, 2005). The 2011-2012 National Health and Nutrition Examination Survey 
(NHANES), a study of US residents, found higher Mn levels in the younger population, 
with the highest levels in one year old infants (Oulhote et al., 2014). These age-related 
factors can increase the risk of neurotoxicity following exposure. 
Alternatively, the very old are a population of special concern, because of the 
large number of people who develop idiopathic Parkinsonism. Brain regions such as the 
globus pallidus, substantia nigra and striatum are involved in both Mn neurotoxicity and 




could be “pushed over the edge” by increased doses of Mn (Mena et al., 1969). For 
example, in one of our occupational exposure studies, we found that smelters without 
clinical symptoms performed significantly worse on the Purdue Pegboard test, which is a 
measure of fine motor coordination, than control subjects. The scores got worse with age, 
which was not unexpected as fine motor coordination declines with age. However, Mn 
exposure appears to exacerbate this decline (Cowan et al., 2009b). 
Gender is another common factor which may influence an individual’s 
susceptibility to Mn toxicity. The 2011-2012 NHANES study of U.S. residents reported 
significantly higher blood Mn levels in women of all ethnicities than men. The authors 
suggest metabolic differences in the regulation of Mn between men and women may 
underlie the difference (Oulhote et al., 2014). A recent study among the Chinese general 
population also indicates that women’s blood Mn levels are about 29% higher than men’s 
(Zhang et al., 2015), consistent with reports in the literature that Korean and Italian 
women’s Mn levels are 25% higher (Bocca et al., 2011; Lee et al., 2012) and Canadian 
women have about 23% higher levels (Clark et al., 2007) than the respective men’s 
population.  
Gender may also be a contributing factor to developing cardiovascular toxicity 
after Mn exposure. In a study of male and female smelters exposed to Mn, female 
smelters had significantly shorter P-R intervals compared to controls and there was no 
difference in males. QRS and T waves were also significantly different for female 
smelters (Jiang and Zheng, 2005). Ethnicity could potentially be a factor that could 




tended to accumulate significantly more Mn than either non-Hispanic Caucasians or non-
Hispanic black individuals (Oulhote et al., 2014). 
Persons with iron deficiency are of special concern, because animal evidence 
indicates that gastrointestinal absorption of manganese is enhanced by iron deficiency 
(Mena et al., 1969). 
While pregnancy is not a pre-existing condition, it is a condition during which the 
susceptibility to Mn toxicity may be increased. Again, the 2011-2012 NHANES 
demonstrates that pregnant women accumulate higher levels of Mn than do other persons 
(Oulhote et al., 2014). In a recent study of maternal blood Mn levels and 
neurodevelopment of infants at 6 months of age, researchers discovered significant 
associations between the mother blood Mn levels and their children’s scores on mental 
and psychomotor developmental indexes. Interestingly, both high and low Mn blood 
levels were associated with lower scores (Chung et al., 2015). Maternal blood Mn levels 
have also been shown to be associated with inhibited enzyme activity of newborn 
erythrocyte Ca-pump at both low and high levels of maternal Mn (Yazbeck et al., 2006). 
A study conducted among pregnant women from Paris suggests that environmental 
exposure to Mn may increase the risk of preeclampsia. Mn cord blood concentrations in 
that study were significantly higher in women with preeclampsia (Vigeh et al., 2006). 
 From a mechanistic point of view, SLC30A10, a solute carrier (family 30 and 
member 10), has been suggested to regulate Mn export from the cells. This protein is 
highly expressed in the liver with a higher specificity for Mn than Zn. Genetic alterations 
in the SLC30A10 enzyme have recently been discovered. An autosomal recessive 




et al., 2013; Tuschl et al., 2013) and results in a pleomorphic phenotype, including 
dystonia and adult-onset Parkinsonism (Leyva-Illades et al., 2014).  
 
1.6 Diagnosis and Clinical Intervention 
 
1.6.1 Biomarkers of Mn exposure 
In Mn occupational exposures, the symptoms often develop quickly because the 
exposure levels are relatively high. In comparison, symptoms resulting from 
environmental exposures may be much more subtle and thus difficult to detect because 
they develop slowly, over a lifetime. Thus, it is crucial to detect these changes with a 
reliable biomarker in order to prevent the irreversible damage or the loss of function 
resulting from Mn toxicity. The biomarkers associated with monitoring Mn exposure in 












































































































































Blood and urine are the most commonly used biological matrices for 
biomonitoring. However, the poor relationships between Mn concentrations in blood and 
urine and the external exposure levels make it very difficult to determine the internal 
exposure (Smith et al., 2007; Zheng et al., 2011). For example, the half-life of Mn in 
blood is less than 2 hours (Zheng et al., 2000). Plasma Mn concentrations measured 
during the dosing phase of a chronic Mn exposure study began to decline after two 
weeks, although Mn exposure was still ongoing (O’Neal et al., 2014a) Mn can be 
detected in human saliva samples. Our human study on Mn-exposed welders found that 
changes of saliva Mn concentrations mirrored those of serum Mn levels. But, because of 
a fairly large variation in saliva Mn levels, the authors did not recommend to use saliva 
Mn to assess Mn exposure (Wang et al., 2008). Because more than 95% of Mn is 
eliminated in bile to feces, urine Mn levels are expected to be very low (Schroeder et al., 
1966). For these reasons, we do not recommend using Mn levels in blood, urine or saliva 
as the biomarkers of Mn exposure.  
Attempts to identify additional non-invasive biomarkers have concluded that 
using hair and nail samples may be a possibility. In our own studies (Cowan et al., 
2009a,b), we collected hair and nail samples from smelters and control subjects. The data 
showed such vast variation that we believe it would be misleading to report these data. A 
thorough, yet rapid process must be developed in order to eliminate external 
contamination before hair and nail samples can be used in research. Regardless, studies 
of residents living near a ferromanganese refinery in Brazil have shown that significant 
correlations exist between hair and fingernail Mn levels and the performance on 




recently suggested using toenail Mn concentration as a biomarker of occupational 
welding fume exposure (Grashow et al., 2014); their study, however, did not relate the 
toenail Mn level to any biological outcomes.  
In a study of Mn-exposed smelters, Mn concentrations in plasma and erythrocytes 
were found to increase with a corresponding decrease of Fe concentrations in plasma and 
erythrocytes (Cowan et al., 2009a,b). Since Mn concentrations reflect the environmental 
exposure and Fe concentrations reflect a biological response to Mn exposure, combining 
both parameters by dividing the Mn concentration by the Fe concentration (i.e., 
MnC/FeC) would enlarge the difference between groups and therefore increase the 
sensitivity. This thought process led to the development of a concept of Mn/Fe ratio in 
plasma (pMIR) or erythrocytes (eMIR) (Cowan et al., 2009a). Because there is a 
significant correlation between pMIR and eMIR to airborne Mn concentration, both 
pMIR and eMIR appear to be good candidates as the biomarkers for Mn exposure 
assessment. Nonetheless, the same study also showed a better correlation between eMIR 
and low- or high- exposure outcomes (Cowan et al., 2009a). The utility of pMIR in 
environmental exposure assessment requires more rigorous testing. Additionally, as Mn-
citrate in blood rapidly enters brain, elevated levels of plasma or serum Mn-citrate may 
be a biomarker of elevated risk of Mn-dependent neurological disorders in occupational 
health (Michalke and Fernsebner, 2014). 
A relatively long half-life (about 8-9 years in human) of Mn in the skeletal system 
(see above) renders bone Mn concentration an ideal indicator to assess the body burden 
of Mn. The technical challenge has always been the development of equipment with 




now become a reality. In recently published manuscripts, Nie and colleagues have 
optimized and verified a neutron activation-based analysis (NAA) technique for 
noninvasive, real-time quantification of Mn concentrations in bone. The equipment, at 
this writing, is compact enough to be transportable to the sites for testing human workers 
and subjects. The method is sensitive and can quantify Mn concentrations as low as 0.5 
ppm of Mn in bone (Liu et al., 2014; Liu et al., 2013) and recently even lower to 0.3 ppm 
(personal communication).  
Another non-invasive technique that can be used to analyze Mn exposure in vivo 
is MRI.  Mn accumulation in the brain can be visualized as an increased T1-weighted 
“hyper-intense” MRI signal. By dividing the signal observed in the globus pallidus by the 
signal observed in the white matter in the frontal cortex and multiplying by 100, a pallidal 
index (PI) can be calculated to quantify Mn intensity. The PI has been proven to be a 
reliable marker for Mn exposure (Dydak et al., 2011; Jiang et al., 2007). Workers with 
more than 5 years’ experience showed nearly 100% occurrence of enhanced PI, 
suggesting that the PI is specific for Mn exposure even when no clinical symptoms are 
evident (Jiang et al., 2007). One downside for using MRI is that it is only good for recent 
exposures. In human studies of smelters or intravenous ephedrone users, the signal in the 
globus pallidus almost completely disappears 5-6 months after cessation of exposure 
(Jiang et al., 2007; Sikk et al., 2011).  
Magnetic resonance spectroscopy (MRS) is another useful technique to quantify 
neurochemical markers associated with Mn exposure (Jiang et al., 2007). Quantitation of 
GABA, glutamate, total creatine (tCr), and N-acetyl-aspartate (NAA)/tCr values, along 




ganglia of Mn-exposed smelters, levels of GABA were nearly doubled, whereas the mean 
airborne Mn level was only 0.18 mg/m3, which is below the previous occupational 
standard (OSHA, 2013). This may indicate an early metabolic or pathological change 
associated with low-level Mn exposure and MRS appears capable of detecting these 
biochemical changes before the full-blown symptoms become evident (Dydak et al., 
2011). 
For animal researchers, recent advancement in the synchrotron XRF imaging 
technique allows to visualize the concentration and distribution pattern of multiple metals 
in brain. The technique can now reach the resolution to the single cell level (Robison et 
al., 2013). 
 
1.6.2 Clinical Intervention 
The foremost therapeutic strategy in treatment of Mn toxicity is to remove the 
patient from the source of the Mn exposure. If the intoxication is life threatening, the 
procedures to relieve the critical signs and symptoms should first be employed. For a 
thorough treatment, chelation therapies can help reduce the body burden of Mn; but such 
treatments may not be able to improve symptoms. Another possible therapy includes Fe 
supplementation. 
Chelation of free Mn with intravenous EDTA has been shown to increase Mn 
excretion in urine and decrease Mn concentrations in blood; but chelation does not 
significantly improve patients’ clinical symptoms (Crossgrove and Zheng, 2004; Jiang et 
al., 2006). A recent report by Tuschl et al., (2013) demonstrates that two patients with 




increased urinary excretion of Mn. Whole blood Mn levels and the MRI signals in the 
globus pallidus were also reduced (Tuschl et al., 2013). In vitro studies have documented 
that EDTA can effectively block toxic effects of Mn on mitochondrial oxygen 
consumption when added either before or after Mn exposure (Liu et al., 2013). Thus, for 
the purpose of reducing Mn in the blood compartment in the initial emergency phase, 
EDTA has a therapeutic benefit. However, EDTA molecules are highly water soluble and 
poorly pass across the blood brain barrier. The low brain bioavailability of EDTA limits 
its effectiveness in treatment of Mn intoxication (Jiang et al., 2006). 
Para-aminosalicylic acid (PAS) is an FDA approved drug used for the treatment 
of tuberculosis. Studies mainly in Chinese patients show the promising effectiveness in 
treating severe Mn intoxication with promising prognosis (Jiang et al., 2006). Animal 
studies further verify its chelating effect in removing Mn from the body (Zheng et al., 
2009). As a hard Lewis acid, Mn3+ can form a stable complex with hard donor atoms 
such as oxygen donors in PAS structure, while the Mn2+ cation prefers relatively softer 
donors such as nitrogen, which is also present in PAS structure. Thus, it is possible that 
PAS may form stable complexes with both Mn2+ and Mn3 species and remove them from 
where they are stored. Moreover, the salicylate structure in PAS, which has a proven anti-
inflammatory effect, may contribute to the therapeutic prognosis of PAS in treatment of 
manganism (Jiang et al., 2006; Yoon et al., 2009). Our recent studies also demonstrated 
that the parent PAS was found predominantly in blood and in choroid plexus tissues, 
whereas its metabolite AcPAS was found in brain parenchyma, CSF, choroid plexus and 
capillary fractions (Hong et al., 2011). Both PAS and AcPAS were transported in the 




superfamily of ATP-binding cassette (ABC) transporters. However, the removal or efflux 
of PAS from brain parenchyma into blood was mediated by the multidrug resistance 
protein 1 (MDR1), also called P-glycoprotein (Hong et al., 2014).  
One additional therapy includes Fe supplementation. In a pilot study with a 
sample size of one, Tuschl et al. (2013) showed that Fe supplementation, in addition to 
chelation therapy, led to a marked improvement of neurological symptoms, whereas the 
chelation therapy alone did little to improve symptoms. The authors proposed that 
supplementing with Fe may help reduce blood Mn levels and lower Mn body burden 
(Tuschl et al., 2013). 
 
1.7 Discussion 
The past decade is a thriving period in the history of Mn research. The total 
volume of publications related to “manganese toxicity” by a PubMed search in the last 11 
years is 1,619 (from our last published review on 1 April 2004 to this writing on 5 April 
2015), which far exceeds the cumulative numbers of 1,199 published papers on Mn 
toxicity for the past 167 years ever since Couper (Couper, 1837) reported on the first case 
of manganism in 1837 (~ to 31 March 2004). On a more fundamental level, the essence 
of what we consider to be a Mn exposure has undergone a significant change, from 
traditionally recognized occupational manganism to low-level Mn exposures in a variety 
of environmental settings, nutritional sources, contaminated foods, infant formulas, and 
water, soil and air with natural or man-made contaminations. Cumulative evidence on Mn 
toxicities and the vast public interest in this metal speak volumes of its public health 




some forms of effective clinical interventions, and any applicable strategy for prevention. 
Thus, we predict that the research on Mn toxicity is far from finished and will become 
even more productive in the coming decade.  
 
1.8 Research Challenges 
 The research challenges addressed by this dissertation are as follows: i) the lack 
of knowledge in toxicokinetic behavior of Mn in bone and the association between bone 
Mn levels and brain Mn levels, ii) the lack of understanding in changes in common 
neurotransmitters associated with Parkinsonian disorders following subchronic exposure 
to Mn, iii) the lack of evidence as to whether Mn affects adult neurogenesis, and iv) the 
lack of research to understand whether and how Cu dyshomeostasis impacts adult 
neurogenesis. 
 
1.9 Central Hypothesis 
The central hypothesis under investigation in this doctoral dissertation is that Mn 
exposure leads to substantial accumulation of Mn in the body, particularly in bone tissues 
and produces subclinical effects in the CNS, including alteration of levels of critical 
neurotransmitters in brain. Mn accumulation may result in diminished neuronal repair 








1.10 Specific Aims to Test Central Hypothesis 
 To test the central hypothesis in this doctoral dissertation, we have designed and 
accomplished the following specific aims: 
1. Determine the toxicokinetic parameters (absorption, distribution, and 
elimination) of Mn in bone tissue. The toxicokinetics of Mn in bone were determined 
by measuring Mn content in bone using atomic absorption spectroscopy (AAS) at various 
times during the accumulation and elimination phases after oral dosing. The rates with 
which Mn accumulates and eliminates from bone tissues were also investigated. Several 
bones with different composition were analyzed to determine if bone-specific differences 
existed. Lastly, correlations between brain and bone Mn levels were evaluated to identify 
if bone Mn concentrations accurately represent brain Mn concentrations. Rationale: 
Approximately 40% of the body burden of Mn is stored in bone. This is an important first 
step to determining if and how Mn stored in bone may be released over time, serving as 
an endogenous source of continued Mn exposure, particularly with regard to the central 
nervous system. 
2. Characterize Mn accumulation in rat brain after exposure and investigate the 
effects on regional neurochemistry. In this aim, we quantified Mn concentrations and 
neurotransmitter levels in the central nervous system using AAS and high performance 
liquid chromatography (HPLC). We further investigated the resulting changes in 
monoamines using immunohistochemistry to determine if the enzyme responsible for the 
metabolism of dopamine, tyrosine hydroxylase was altered. Levels of DARPP-32, a 
marker of striatal medium spiny neurons, were also investigated. Lastly, we determined if 




rat brain slices. Rationale: Studies in literature have investigated changes in 
neurochemistry; yet, the results remain inconclusive. Depending on the dose level of Mn 
used or the duration of exposure, the results, particularly with regard to dopamine, vary 
considerably. This research utilized several dose levels and examined multiple brain 
regions to determine if a dose response relationship existed and whether effects were 
limited to a particular region. 
3. Identify how Mn exposure affects the processes of neurogenesis and gliogenesis in 
the adult subventricular zone. In this aim, we investigated differential changes in 
expression of BrdU, DCX, and GFAP in the SVZ following intranasal instillation of Mn 
using immunohistochemistry (IHC) techniques and confocal quantification. The cells that 
reside in this region may migrate to the olfactory bulb where they undergo further 
changes. Expression of BrdU, DCX, and GFAP were also evaluated in the various cell 
layers of the olfactory bulb. A sub-aim of this hypothesis was to characterize the 
intranasal instillation technique for future use in studies of Mn neurotoxicity and adult 
neurogenesis by investigating changes in neurochemistry using HPLC and expression of 
mRNA and protein levels of selected metal transporters. Physiological measurements 
were also made to determine if overt toxicity or immune response occurs following 
intranasal Mn exposure.  Rationale: Recent work from our lab has shown that Mn 
exposure by intranasal instillation alters adult neurogenesis in the SVZ. This is the first 
application of the intranasal instillation technique to studies of adult neurogenesis 
following Mn exposure. These studies are of critical importance given that the primary 




Investigating changes in the SVZ and OB could provide new evidence for the association 
between Mn exposure and Parkinson’s disease.  
 
 
1.11 Significance of the Research 
The interaction between Mn neurotoxicity and Parkinson’s disease is complex and 
not completely understood. Many associations between Mn-induced Parkinsonism and 
Parkinson’s disease have been found in humans but the results have often been 
contradictory. Additionally, recent evidence from our lab has suggested that Mn exposure 
alters processes of neuronal repair and adult neurogenesis in the SVZ known to be active 
in Parkinson’s disease. It is well-warranted to further investigate changes in this region as 
well as changes in neurochemistry following Mn exposure because alterations in these 
processes could lead to dysregulation of a variety of other processes in the body. An 
understanding of how Mn exposure influences adult neurogenesis and how Cu levels are 
regulated in the SVZ are critical for the development of effective therapeutic strategies in 
neurodegenerative diseases which implicate Cu dysregulation in their pathologies.  
The contribution of our research is expected to be a detailed understanding of how 
Mn exposure affects neurochemistry and adult neurogenesis. Specifically, we expect to 1) 
elucidate toxicokinetic parameters of Mn in bone which will help in the search for a 
suitable biomarker of Mn exposure and determine if Mn stored in bone can serve as an 
internal depot of Mn for extended durations, 2) determine how Mn exposure regionally 
affects brain neurochemistry and potentially uncover dose-response relationships, 3) 
demonstrate that the intranasal route of Mn exposure is a suitable method for studies of 




brain repair mechanisms, specifically the proliferation and differentiation of neural 
progenitor stem cells.  
The experimental methodologies to be used are rigorous and diverse, including 
atomic absorption spectroscopy, high performance liquid chromatography, 
immunohistochemistry, Western blotting, quantitative polymerase chain reaction (qPCR), 
and behavioral assays to pursue important new information about Mn toxicity in the 
mammalian system. Understanding how brain and bone Mn levels correlate after Mn 
exposure will help discover a novel biomarker suitable for the assessment of Mn 
exposure in humans. Importantly, the primary route of Mn exposure in the human 
population is inhalation; so utilizing an intranasal route of exposure could more closely 
mirror what occurs in the human population. No other researchers have used this 
technique to investigate metal toxicity and neurogenesis. By this pathway, environmental 
contaminants, including Mn, directly interact with the central nervous system and 
therefore further investigation of this exposure route is well warranted. 
Completion of this work will provide evidence of Mn interaction with neuronal 
repair mechanisms and lead to a new area of toxicology research, specifically metals 
toxicology. A better understanding of these processes may present novel pathways and 
target strategies for regulating the processes of adult neurogenesis in the SVZ and SGZ 
by guiding and encouraging the existing processes. This work will assist future 
researchers investigating Parkinson’s disease, Alzheimer’s disease, Amyotrophic Lateral 
Sclerosis, Wilson’s and Menke’s diseases as well as stroke, and traumatic brain injury, 
among many other applications,  making our work in the field of adult neurogenesis 




applied to the analysis of other regions with more limited neurogenic capabilities, 
including the hypothalamus, further extending the scope of the research. 
 
1.12 Structure of the Dissertation 
This dissertation is organized in the following sequence: the introduction and 
background are presented in Chapter 1, which provides an in-depth analysis of the new 
findings from the last 10 years. Chapter 2 is devoted to the toxicokinetic understanding of 
Mn in bone and its relationship to Mn accumulation in brain. This is followed by a 
thorough analysis of neurotransmitter concentrations in brain as a result of Mn exposure 
in Chapter 3. Chapter 4 details the changes to neurogenic function that occur in the 
subventricular zone and olfactory bulb following intranasal Mn exposure. Finally, 
Chapter 5 summarizes the findings and discusses the future directions of this work. 
Notably, most of the research data have been published (i.e., data in Chapters 2 and 3) or 
are prepared for publication (i.e., data in Chapter 4). Thus, the presentation in these 
chapters follows the structure of published papers. To maintain the flow of each 





CHAPTER 2: MANGANESE ACCUMULATION IN BONE FOLLOWING CHRONIC 





Literature data indicate that bone is a major storage organ for manganese (Mn), 
accounting for 43% of total body Mn. However, the kinetic nature of Mn in bone, 
especially the half-life (t1/2), remained unknown. The study presented in this chapter was 
designed to understand the time-dependence of Mn distribution in rat bone after chronic 
oral exposure. Adult male rats received 50 mg Mn/kg (as MnCl2) by oral gavage, 5 days 
per week, for up to 10 weeks. Animals were euthanized every two weeks during Mn 
administration for the uptake study, and on day 1, week 2, 4, 8, or 12 after the cessation 
at 6-week Mn exposure for the t1/2 study. Mn concentrations in bone (MnBn) were 
determined by AAS analysis. By the end of 6-week’s treatment, MnBn appeared to reach 
the steady state (Tss) level, about 2-3.2 fold higher than MnBn at day 0. Kinetic 
calculation revealed t1/2s of Mn in femur, tibia, and humerus bone of 77 (r=0.978), 263 
(r=0.988), and 429 (r=0.994) days, respectively; the average t1/2 in rat skeleton was about 




Mn levels in striatum, hippocampus, and CSF. These data support MnBn as a useful 
biomarker of Mn exposure.   
 
2.2 Introduction 
Occupational exposure to manganese (Mn), such as in mining, smelting, welding 
or dry-cell battery production, has been associated with a neurodegenerative parkinsonian 
disorder clinically called manganism (Barbeau et al., 1976; Chandra et al., 1981; 
Crossgrove and Zheng, 2004; Jiang et al., 2006). Environmental exposure to this toxic 
metal has also been linked to the consumption of Mn-containing pesticides and 
contamination in drinking water and food (Bouchard et al., 2011). Addition of Mn to 
gasoline as the anti-knocking reagent, methylcyclopentadienyl Mn tricarbonyl (MMT) 
further raises concerns about health risks associated with a potential increase in 
environmental levels of Mn (Butcher et al., 1999; Sierra et al., 1995).  Recently, 
increasing numbers of cases of Mn-induced Parkinsonism have been observed among 
drug addicts using ephedrone (Sikk et al., 2011). It is because of rising public health 
concerns that a thorough understanding of Mn neurotoxicity, including its distribution in 
the body and mechanism of action, is well justified.  
Patients suffering from manganism have signs and symptoms closely resembling, 
but not identical to, Parkinson’s disease (PD) (Aschner et al., 2007; Jiang et al., 2006; 
Racette et al., 2012). Recent data also show that Mn may play a role in PD etiology 
(DeWitt et al., 2013; Lucchini et al., 2007). Since clinically manifested Mn neurotoxicity 
is usually progressive and irreversible, early diagnosis becomes critical to treatment and 




and health risk have focused on Mn concentrations in blood, urine, and/or nail. These 
biomarkers, however, are of limited use for exposure assessment in that primarily 
intracellular accumulation of Mn renders blood, urine, or nail Mn levels inaccurate in 
reflecting the true body burden of Mn (Apostoli et al., 2000; Zheng and Monnot, 2012). 
For example, in group comparisons among active workers, blood Mn has some utility for 
distinguishing exposed from unexposed subjects; yet a large variability in mean values 
renders it insensitive for discriminating one individual from the rest of the study 
population. Human studies using magnetic resonance imaging (MRI), in combination 
with non-invasive assessment of γ-aminobutyric acid (GABA) by magnetic resonance 
spectroscopy (MRS), have provided evidence of Mn exposure in patients devoid of 
clinical symptoms of Mn intoxication (Dydak et al., 2011; Jiang et al., 2007).  These 
methods, however, do not provide an adequate estimation of Mn body burden in a long-
term, low-dose Mn exposure scenario (Zheng and Monnot, 2012). Thus, to date, a 
reliable biomarker to accurately reflect Mn exposure or body burden remains unavailable.  
Data in literature suggest that, at normal physiological conditions, Mn 
accumulates extensively in human bone tissues (Pejovic-Milic et al., 2009; Schroeder et 
al., 1966; Zaichick et al., 2011). Schroeder et al. (1966) observed an average 
concentration of 2 mg/kg of Mn in bone ash, which gives rise to about 32.5% of body Mn 
in bone, according to our recent calculation (Liu et al., 2013). The International 
Commission on Radiological Protection (ICRP) has reported approximately 40% of body 
Mn accumulates in bone (ICRP, 1972). Information from animal studies of Mn 
accumulation in bone can be found in literature, albeit is very limited (Dorman et al., 




modeling approach, Andersen et al. (1999) reported that Mn stored in bone tissues 
contributed to over 40% of body Mn; the estimate is closer to the aforementioned human 
data. Studies by Furchner et al. (1966) using radioactive 54Mn administered orally to rats 
at a normal physiological dose have found that the radioisotope in bone had a half-life of 
more than 50 days, which was much longer than the 54Mn half-life in other rat tissues.  
Another study by Newland et al. (1987) in primates using 54Mn reported that Mn had a 
relatively long half-life of about 220 days in the whole head after inhalation exposure. In 
the same study, the researchers found that the half-life of 54Mn in brain tissues from the 
same animals was much shorter; hence they ascribed a long half-life of 54Mn in the head 
to 54Mn present in the skull or to replenishment from other depots (Newland et al., 1987). 
These data have clearly established that bone is one of the major organs for long-term 
storage of Mn in the body. Thus, a reliable assessment of Mn health benefits or risks 
should take into account the extensive Mn deposition in bone. However, knowledge on 
the rate of Mn accumulation in human or animal bone, and the pertinent biological half-
life of Mn in bone was incomplete.   
Recent advances in neutron activation-based detection technology has made it 
possible to develop a portable neutron activation analysis (NAA) system for quantifying 
MnBn (Aslam et al., 2008; Liu et al., 2013; Pejovic-Milic et al., 2009). This highly 
innovative technique uses a portable deuterium–deuterium neutron generator (as the 
neutron source) to detect Mn in bone, non-invasively and in real time, in human subjects. 
To support this technical innovation, there was a need to understand the toxicokinetics of 




The purposes of the current study were to (1) characterize the time-dependent 
accumulation of Mn in rat bone following chronic oral administration of Mn to animals; 
(2) determine the elimination t1/2 of Mn in bone tissues; (3) investigate if bone samples 
collected from different body parts had similar or different kinetic characteristics; and (4) 
seek the correlations between MnBn and Mn concentrations in select brain regions 
known to be targets of Mn neurotoxicity. Understanding the time-dependent changes of 
tissue distribution of Mn within bone, central nervous system (CNS), and other tissues 
will help understand Mn neurotoxicity described in the following chapters. 
 
2.3 Materials and Methods 
 
2.3.1 Chemicals 
Chemical reagents were purchased from the following sources: Mn chloride 
tetrahydrate (MnCl2•4H2O) from Fisher Scientific (Pittsburgh, PA); Mn and Cu standard 
solutions were from SCP Science (Champlain, NY); ketamine from Fort Dodge (Fort 
Dodge, IA ); xylazine from Vedco (St. Joseph, MO). All reagents were analytical grade, 










2.3.2 Experimental design 




Figure 1. Chapter 2 Experimental Design. Bones were collected and analyzed at each 
time point shown. The top row indicates ongoing dose administration. The bottom row 


















Phase 1 studies were designed to determine the time course of Mn accumulation 
in bone. Rats received daily administration of 50 mg Mn/kg as MnCl2 by oral gavage, 5 
days per week for the period of time specified in the above illustration. In this phase, dose 
administration lasted up to 10 weeks with cohorts of animals euthanized every two weeks 
to determine the steady state Mn concentrations (Tss) in bone following oral exposure.   
Phase 2 studies were designed to determine the elimination t1/2 of Mn from bone 
tissues. The results from phase 1 suggest a Tss was reached by 6 weeks of continuous Mn 
exposure. After the last dose of the week-6 dose administration, animals were euthanized 
at 24 hours, 2 weeks, 1, 2 and 3 months to determine t1/2 of MnBn.  
   
2.3.3 Animals and Mn Administration 
Male Sprague Dawley rats were purchased from Harlan Laboratories, Inc. 
(Indianapolis, IN). Upon arrival, animals were housed in a temperature-controlled, 12-h 
light/dark cycle room and allowed to acclimate for one week prior to experimentation. At 
the time of use, rats were 8 weeks old and weighed 220-250 g. Animals had ad libitum 
access to filtered tap water and pelleted rat chow (Harlan Teklad 2018 Diet, Harlan 
Laboratories). The studies were approved by the Institutional Animal Care and Use 
Committee at Purdue University. 
MnCl2•4H2O dissolved in sterile saline was administrated to rats by oral gavage 
of 50 mg Mn/kg, once per day, 5 days per week, for up to 10 weeks. This dose regimen 
was selected based on our preliminary study showing plasma Mn concentration of ~25 
µg/L after 2-week oral doses, which is comparable to blood Mn levels in Mn-exposed 




blood Mn concentrations between 4-15 µg/L (Inoue and Makita, 1996; Vezér et al., 
2007). Our own human study among 39 Mn-poisoned welders in Beijing reveals that the 
welders with a distinct manganism have a blood Mn level in the range of 8.2-36 µg/L 
(Crossgrove and Zheng, 2004). Thus, a continuous daily oral gavage at 50 mg/kg would 
likely result in a steady-state blood concentration similar to chronic occupational 
exposure in humans. The daily equivalent volume (4 ml/kg) of sterile saline was given to 
control animals. Twenty-four hours after the last injection, rats were anesthetized with 
ketamine/xylazine (75:10 mg/kg; 1 mg/kg, ip). Cerebrospinal fluid (CSF) samples, free of 
blood, were collected using a 26G butterfly needle inserted between the protuberance and 
the spine of the atlas, and blood samples were obtained from the descending aorta and 
processed for plasma. Rat brains were dissected to harvest choroid plexus from lateral 
and third ventricles, hippocampus, striatum, and frontal cortex. Samples were stored at -
80°C for later analysis. 
 
2.3.4 Determination of Mn, Fe, Cu and Zn Concentrations by AAS 
All brain and bone samples were digested with concentrated ultrapure nitric acid 
in a MARSXpress microwave-accelerated reaction system. Plasma and CSF samples 
were digested overnight with nitric acid in a drying oven at 55°C. An Agilent 
Technologies 200 Series SpectrAA with a GTA 120 graphite tube atomizer was used to 
quantify Mn, Fe, Cu and Zn concentrations. Digested samples were diluted 50, 500, or 
1000 times with 1.0% (v/v) HNO3 in order to keep the readings within the concentration 
range of the standard curves. Ranges of calibration standards were 0-5 μg/l for Mn, 0-10 




0.09 ng/ml, 0.18 ng/ml, 0.9 ng/ml, and 0.28 ng/ml, respectively, of the final assay 
solution (Zheng et al., 1998, 1999, 2009). 
 
2.3.5 Toxicokinetic and Statistics Analysis 
Values of MnBn from various body parts were plotted as a function of time. 
Calculation of the terminal-phase elimination rate constant (Ke) was based on the 
assumption of first-order elimination kinetics (Gibaldi and Perrier, 1982; Zheng et al., 
2001). A linear regression analysis was used to estimate the Ke of individual curves 
obtained from different body bones, from which the t1/2 was obtained using the following 
equation:  




All data are expressed as mean ± S.D.; statistical analyses of the differences 
between groups were carried out by one-way ANOVA with post hoc comparisons by 
Dunnett’s test or Student’s t-test using SPSS for Windows (version 20.0). The differences 





2.4.1 Increased Mn concentrations in body fluids after Mn exposure 
Following oral chronic Mn exposure, the plasma concentrations of Mn were 




exposure (Fig. 2). After 4 weeks of Mn dosing, plasma Mn concentration remained 
significantly higher compared to the baseline, but it declined from the 2 week value (Fig. 
2). Plasma Mn concentrations were not significantly different after 6, 8, or 10 weeks of 
Mn exposure as compared to the baseline. Similarly, Mn concentration in CSF was 
significantly increased compared to baseline after 2 weeks of Mn exposure (p < 0.05; Fig. 
2). Interestingly, Mn concentrations in CSF samples remained significantly higher at 4, 6, 
8, and 10 weeks of dosing in comparison to the baseline value (p < 0.01; Fig. 2). Between 














Figure 2. Time Course of Mn Concentrations in Plasma and Cerebrospinal Fluid.  
Rats received 50 mg Mn/kg as MnCl2 by oral gavage once daily, five days per week for  
the time indicated. Mn concentrations in plasma and CSF were determined by AAS. Data  













2.4.2 Increased Mn Concentrations in Bones after Mn Exposure 
 Mn accumulation in bone was investigated in bone samples including femur, 
tibia, humerus, and parietal bones. While chronic Mn oral exposure did not significantly 
affect animals’ body weights after 6 weeks exposure, the weight of femur bones was 
significantly reduced compared to controls (-8.5%, p < 0.01; Table 3). Concentrations of 
Mn in bone appeared to be elevated after only two-weeks of exposure, although the 
values were not statistically significant (Fig. 3). After 4-weeks of exposure, a significant 
accumulation of Mn in bone was observed in all bone samples (p < 0.05; Fig. 3). This 
increase in Mn accumulation in all bone samples continued until the 8th week of Mn 
exposure. Since there were no statistically significant differences between the data points 
from the 6th-, 8th- or 10th-week bone samples, MnBn appeared to reach the steady state 
















Table 3. Changes of Total Body Weight and Femur Bone Weight s after Chronic 
Oral Mn Exposure in Rats. Rats received 50 mg Mn/kg as MnCl2 by oral gavage once 
daily, five days per week, for 6 weeks. Mn concentrations were determined by AAS. Data 
represent mean ± S.D., n = 5-6; * p < 0.05. 
 
Body Weight    Bone Weight 
   Day 0  18 Weeks  Day 0  18 Weeks 
Control  261.6 ± 5.22 354.9 ± 16.24   1.07 ± 0.13 1.30 ± 0.02 












Figure 3. Time-Dependent Accumulation of Mn in Rat Bones.  The animal treatment  
regimen is described in the legend to Fig. 1. Mn concentrations in various bone samples  
were determined by AAS. Data represent mean ± S.D., n = 5-6; * p < 0.05, ** p < 0.01  
indicating group comparisons made between samples collected at times after Mn  










2.4.3 Mn t1/2 in Rat Bones 
To determine the elimination t1/2, animals were exposed to Mn for 6 weeks until 
the Tss was reached. Bone tissues were then dissected at 24 hours, 2 weeks, 1, 2 and 3 
months following exposure cessation for AAS quantification of Mn concentrations in 
femur, tibia, humerus, and parietal bone. Average values for each type of bone were 
plotted on a semi-log scale over time to yield four separate regression lines. The slopes of 
these regression lines were taken as the individual elimination rate constant Ke and used 
to calculate the MnBn t1/2 for each bone type. Our calculations result in t1/2s of 77, 263, 
429, and 690 days for femur, tibia, humerus, and parietal bones, respectively. To estimate 
the Mn t1/2 in the whole rat skeleton, the values for all bones at each time point were 
averaged. Following the same procedure used to calculate the t1/2 in individual bones, the 







Figure 4. Terminal Phase Elimination Half-Life (t1/2) of Mn in bones. Rats received  
50 mg Mn/kg as MnCl2 by oral gavage once daily, five days per week for 6 weeks.  
Groups of animals were euthanized at the times indicated. The values of MnBn were  
plotted as a function of time; the elimination rate constants were estimated by linear  
regression analysis, and used to calculate the elimination t1/2. To estimate average t1/2 in  
rat skeleton, all values at each time point were averaged and the linear regression method  


















2.4.4 Correlations between Mn Concentrations in Bone and Mn Concentrations in 
Selected Brain Regions 
To test the hypothesis that Mn stored in bone tissues may serve as the internal 
source of Mn in brain, a linear regression method was used to correlate Mn 
concentrations in the striatum and hippocampus with MnBn from the same animals. 
Since the choroid plexus in brain ventricles transports metals and secretes the CSF, which 
provides the internal milieu of the CNS (Zheng et al., 2003), correlations between MnBn 
and Mn concentration in choroid plexus and CSF collected from the same animals were 
also investigated. The results showed that there were strong correlations between MnBn 
and Mn levels in striatum (correlation coefficient r=0.7549, p < 0.001) and hippocampus 
(r=0.7823, p < 0.001). Interestingly, the Mn concentration in the choroid plexus was also 
strongly associated with MnBn (r=0.6519, p < 0.001), so was the correlation between 
MnBn and CSF (r=0.7204, p < 0.001), suggesting that bone could potentially serve as an 











Figure 5. Changes of Mn Concentrations in Brain, Choroid Plexus and CSF as a  
Function of Mn Concentration in Bone. Mn concentrations in all tissues were  






2.4.5 Correlation of Mn in Bone with Concentrations of Fe, Cu, and Zn in Rat Skeleton 
 To understand how Mn accumulation in bone affects accumulation of other 
metals, such as Fe, Cu, and Zn in the rat skeleton, the linear regression method was again 
used to correlate MnBn with concentrations of Fe, Cu, and Zn in femur, tibia, and 
humerus bones from the same animals. The results showed there were strong positive 
correlations between MnBn and Fe levels in the rat bones (r=0.8509; p < 0.001), and 
MnBn and Zn (r=0.7510; p < 0.001), but an inverse correlation between MnBn and Cu 
(r=-0.7259; p < 0.001; Fig. 6). The results suggested that Mn accumulation in bone likely 
















Figure 6. Changes of Fe, Cu and Zn Concentrations in Bone as a Function of Mn   
Concentration in Bone. Concentrations of Mn, Fe, Cu and Zn were determined by AAS.  


















2.4.6 MnBn in Rats with Other Mn Exposure Paradigm 
A rapid time-dependent Mn accumulation in bone observed in Phase 1 of this 
study raised the question as to whether alternative Mn dose regimens and routes of 
exposure may lead to similar Mn accumulation in bone. In our previous studies, we have 
used a subchronic Mn exposure model by administering rats 6 mg Mn/kg (low dose) or 
15 mg Mn/kg (high dose) as MnCl2, 5 days per week for 4 weeks by intraperitoneal 
injection, and found significant alterations in neurochemical profiles (O’Neal et al., 
2014b). To investigate bone Mn accumulation in this animal model, rats received ip 
injections of Mn with the same dose regimen. Following 4-weeks ip dose administration, 
MnBn was significantly increased in both exposure groups as compared to controls (49.3 
± 9.3 for low dose, 172.9 ± 35.3 for high dose vs. 13.0 ± 7.8 for control; mean ± S.D. 
µg/g; p < 0.01; Fig. 7). It was apparent that Mn accumulated in bone tissues was in a 






Figure 7. Mn Concentration in Rat Bone after Chronic IP Injection Exposure. Rats 
received 6 mg Mn/kg as MnCl2 by ip. injections once daily, five days per week, for 4 














2.4.7 Mn Concentration in Muscle 
In vivo noninvasive measurements of MnBn (Liu et al., 2013) will likely include 
some contribution of Mn present in skeletal muscle. We determined Mn concentrations in 
muscle in animals receiving oral doses of Mn. The soleus muscle was selected because of 
its proximity to the tibia, one of the bones commonly measured in vivo. This proximity 
makes soleus muscle the ideal candidate for examination because it will directly impact 
measurements of MnBn in humans. The results showed an initial increase of Mn in the 
soleus muscle, which reached a statistical significance after only 4 weeks of dose 
administration (p < 0.05; Fig. 8). However, similar to the Mn concentrations in plasma 
and CSF, the levels of Mn began to decrease despite continued administration of Mn, and 
stayed relatively unchanged in comparison to controls at time 0 (~0.35-0.40 µg/L). Thus, 
it seems likely that under long-term, chronic exposure conditions, the Mn concentration 








Figure 8. Mn Concentration in Muscle after Chronic Oral Mn Exposure. Mn  
concentrations in soleus muscle were determined by AAS. Data represent mean ± S.D., 
n = 5-6; * p < 0.05. Figure 17. Time-dependent accumulation of Mn in selected brain  
regions following chronic oral Mn exposure. Rats received 50 mg Mn/kg as MnCl2 
by oral gavage once daily, five days per week for the time indicated. Mn concentrations 














This study is the first to report estimations of the t1/2 of Mn in bone after a chronic 
oral Mn exposure. Other reports in literature have described extensive Mn accumulation 
in bone (Pejovic-Milic et al., 2009; Schroeder et al., 1966; Zaichick et al., 2011); yet 
none has calculated the half-life of Mn in the rat skeleton.  
  Occupational exposure to Mn in the air at concentrations from 0.1-1.27 mg/m3 
shows levels of Mn in the blood to be 10.3-12.5 μg/l (Vezér et al., 2007). Among patients 
with clinical signs and symptoms of manganism, the blood Mn concentration varies 
between 4-40 µg/L (Crossgrove and Zheng, 2004; Inoue and Makita, 1996; Jiang, et al., 
2007). Interestingly, the plasma Mn concentration in rats at day 30 following this oral 
dose regimen is ~20 µg/L; the level is highly comparable to human Mn blood level at 
poisoning. Interestingly, the steady-state concentrations of Mn in rat striatum under this 
dose regimen are about 1-1.2 µg/g between four and six weeks of dose administration; 
under this brain concentration range, a significant striatal neurodegenerative injury has 
been observed (Fujioka et al., 2003). Noticeably, environmental exposure to Mn has been 
known to occur through eating foods and drinking water contaminated with Mn (ATSDR, 
2012). Studies of humans drinking contaminated water in Bangladesh and Greece show 
that levels of Mn between 50 μg/l and 8.61 mg/l can cause adverse health effects 
(Hafeman et al., 2007; Kondakis et al., 1989). The LD50 of oral MnCl2 exposure in rats is 
338 mg/kg (McMillian, 1999). Our dose of 50 mg/kg is approximately 15% of this value. 
Although rats were exposed orally in the current study, the ATSDR (2012) reports that 
health effects observed after an oral exposure are similar to those observed after an 




appropriate animal model for chronic Mn intoxication study including Mn accumulation 
and elimination from bone tissues. 
It is interesting to know that in the first 4 weeks of Mn dose administration MnBn 
continued to increase, while the blood Mn concentration started to decline by the end of 
the 4th week of dosing. Although the blood Mn concentration returned to nearly baseline 
level after 10 weeks of exposure, MnBn remained significantly higher than in controls. 
This observation supports the view that a short blood t1/2 of Mn is due primarily to its 
intracellular distribution (Zheng et al., 2000) and thus, Mn blood concentration is deemed 
insufficient for assessment of Mn exposure or health risk (Zheng et al., 2011). Data from 
the current study clearly demonstrate that the bone tissue serves as a storage site upon Mn 
chronic exposure. Indeed, the average t1/2 of MnBn was estimated to be about 143 days. 
In a comparative study of human and rat developmental time points and associated body 
weights, Sengupta (2011) proposes that every 16.7 days throughout the life of the rat is 
equivalent to one human year. Using this analogy, we estimate the half-life of Mn in the 
rat femur to be 4.61 years, tibia 15.75 years, humerus 25.69 years, and parietal bone 
would be an astounding 41.32 years. To estimate the value for the entire skeleton, it is 
more appropriate to take the half-lives of bone sampled from different body parts. Thus, 
by using the average half-life in in the current study, we estimate that the average half-
life of Mn in the rat skeleton corresponds to 8.6 years for humans.  
The current study also reveals an interesting observation, i.e., the shortest half-
lives of Mn are observed in the weight-bearing bones. Specifically, we observed the 
shortest half-lives in femur and tibia bones and the longest in parietal bone. Regarding 




developed for burrowing, running, jumping, and walking. Although not bipedal, rats do 
spend time standing on their hind limbs while exploring or searching for food. This 
potentially puts more pressure on the femur and tibia bones when compared with their 
humerus or parietal bones. This leads to another interesting question as to why the 
weight-bearing bones have a shorter storage time for Mn.  
In both adult humans and rats, the main function of the skeleton is remodeling. 
Bone remodeling consists of both bone formation and resorption. Between the different 
types of bones, there are anatomical and functional differences. For example, the 
perfusion rate within tubular long bones differs between areas of cortical bone such as the 
diaphysis, and areas of trabecular bone, including the femoral head and neck. Tøndevold 
and Eliasen (1982) have found that the perfusion rate is highest in areas with more 
trabecular bone and lowest in the diaphysis with more cortical bone. They also show that 
the perfusion rate is similar between the femur and tibia (Tøndevold and Eliasen, 1982), 
although the differences between these and other bone types, such as parietal bone, 
remain unknown. Serrat et al. (2007) indicate that some bones, such as the humerus, have 
different ossification patterns than does the femur. Bancroft et al. (2002) also suggest that 
the differences in fluid perfusion rates among bone tissues could alter the levels of 
nutrients including intracellular calcium and other biochemical factors, such as 
prostaglandin E2 and cyclooxygenase-2 in bone in vitro. Further, they observe that the 
fluid flow in these tissues mechanically stimulates pressure gradients so to move fluid 
outward into the cortical bone (Bancroft et al., 2002). Taking into account these literature 




and hydrostatic pressure or compression may explain the observed differences in Mn 
half-lives in different bones.  
In the present study, we do not see significant changes in animals’ body weights 
after chronic Mn oral exposure. However, we did observe the weight of femur bone to be 
significantly reduced after 18 weeks of Mn exposure. This observation suggests that in 
addition to simple storage, Mn ions accumulated in bone may have a direct detrimental 
effect on bone’s normal structure and function. In addition, we found that MnBn was 
positively associated with Fe and Zn in bone but inversely related to Cu. The implications 
of these relationships are currently unknown. Thus, Mn-induced osteotoxicity as a result 
of chronic Mn exposure in humans as well as animals deserves further in-depth 
investigation. 
To understand whether MnBn could be used as a potential biomarker for Mn-
induced neurotoxicity, we correlated MnBn with Mn levels in selected brain regions, 
including striatum, hippocampus, and choroid plexus from the same animals. It was 
evident that the values of MnBn were well correlated with each of these brain regions. 
These relationships are important for studies of Mn neurotoxicity in humans, for striatum 
is known to accumulate Mn to a great extent in humans (Dydak et al., 2011; Jiang et al., 
2007), hippocampus is a potential target of Mn toxicity (Wang et al., 2012), and Mn 
accumulation in the choroid plexus is known to cause the dysregulation of the 
homeostasis of iron and copper in the central milieu (Zheng et al., 2003; 2012).   
One of the purposes of this study was to build a theoretical foundation for human 
noninvasive quantitation of MnBn by using a novel deuterium-deuterium (DD) neutron 




transportable version of this system, which has been developed recently at Purdue 
University, has a detection limit of 0.7 ppm (µg/g). Schroeder et al. (1966) report that 
normal human subjects have a MnBn of 2 µg/g, which was determined using postmortem 
human bone tissues. Based on our current data, MnBn at the steady-state exceeds 1 µg/g. 
Thus, this transportable AAS device shall be of practical value in human study. The 
concentration of Mn in muscle was also determined in order to understand the kinetic 
changes of Mn levels in this tissue. Our results demonstrated that the Mn concentration in 
muscle remained constant after chronic exposure. Taken together, we feel that because 
MnBn has a long half-life, is well correlated with levels of Mn in brain and is not 
interfered by Mn in muscle, the MnBn measured in vivo by the transportable NAA 
system would serve as an excellent biomarker of Mn exposure in occupational and 
environmental research.  
This study has limitations. First, the study as designed does not allow us to 
investigate the regional distribution and deposition of Mn within bone. Current studies in 
the lab are investigating the differences in distribution of Mn between cortical and 
trabecular bone. At the time of writing, our preliminary data from animals exposed to 6 
mg Mn/kg as MnCl2 via ip injection five days per week for four weeks suggests that Mn 
accumulates in the trabecular bone of control animals, but in the cortical bone of Mn-
exposed animals. Further work by synchrotron XR technique to depict regional 
distribution of Mn in bone is desirable. Second, our current study does not address how 
Mn ions gain access to bone tissues, what subcellular ligands in bone tissues Mn ions are 
bound with, and whether Mn transporters, such as divalent metal transporter-1 (DMT1) 




metals. Finally, due to the limited budget, the current study was not able to investigate the 
percentage of Mn in bone with regards to the total body burden, although such 
percentages have been reported in literature (see Introduction).  
In summary, the data presented in this report suggest that a 4-week Mn oral 
exposure can lead to a significant accumulation of Mn in bone tissues. The half-lives of 
Mn in rat bone are in the range of 77-690 days with an average of 143 days. Moreover, 
the weight-bearing bones such as femur appear to have a shorter t1/2 than non-weight 
bearing bones. Since brain Mn levels change as a function of MnBn, we propose that the 




CHAPTER 3: SUBCHRONIC MANGANESE EXPOSURE ALTERS 





 High levels of manganese (Mn) in the brain are neurotoxic and result in a 
progressive, irreversible disorder known as manganism which includes both 
psychological and motor disturbances.  Evidence suggests that Mn exposure impacts 
neurotransmitter levels in the brain. However, it remained unclear if subchronic, low-
level Mn exposure resulted in alterations in neurotransmitter systems with concomitant 
behavioral deficits.  The study in this chapter used high performance liquid 
chromatography (HPLC) to quantify neurotransmitter levels in rat striatum, substantia 
nigra, and hippocampus. Subchronic Mn exposure via i.p. injection of 15 mg Mn/kg as 
MnCl2 caused significantly increased dopamine levels in the striatum.  The enhancement 
was accompanied by significantly elevated levels of the dopamine metabolites, DOPAC 
and HVA, in the striatum.  In addition, levels of HVA were significantly increased in the 
substantia nigra and hippocampus. Mn toxicity on neurochemical concentrations in brain 
could be the consequences of Mn accumulation in bones (Chapter 2).  These data indicate 




systems in the rat brain which may be responsible, in part, for observed locomotor 
deficits. The data presented in this chapter may provide clues to understanding the effects 
of Mn exposure on adult neurogenesis (investigated in Chapter 4). 
 
3.2 Introduction 
Manganese (Mn) is an essential trace element required for normal function and 
development of many physiological processes.  In the central nervous system, Mn 
functions as a cofactor for enzymes necessary for neuronal function and neurotransmitter 
biosynthesis, such as superoxide dismutase 2, pyruvate decarboxylase, and glutamine 
synthetase (Aschner et al., 2009; Bowman et al., 2011; Schneider et al., 2009).  Normally, 
regulatory mechanisms carefully maintain homeostatic levels of Mn in the body by 
controlling absorption and elimination of excess metal via hepatobiliary excretion 
(Klaassen, 1976).  However, excess Mn exposure can overload these mechanisms 
(Schneider et al., 2009), leading to Mn accumulation in body tissues, including bone 
(Chapter 2), liver, kidney, and pancreas (Dobson et al., 2004).  Mn  in the 2+ and 3+ states 
readily crosses the blood-brain barrier (BBB) (Aschner et al., 1999) and preferentially 
accumulates in specific brain regions, such as striatum (STR), globus pallidus, 
cerebellum, and hippocampus (HP) (Andersen et al., 2010; Fitsanakis et al., 2008; O'Neal 
and Zheng, 2015).  
Adequate levels of Mn are obtained from food, such as nuts, tea, and legumes, 




soil, contaminated water, and occupational exposure during mining and agricultural 
processes, are potential sources of toxic exposure (Mergler, 1999).  The highest levels of 
exposure are observed in the workplace, where workers chronically exposed to levels < 5 
mg/m3 have reported symptoms of Mn toxicity (Crossgrove & Zheng, 2004). These 
symptoms result from toxic Mn accumulation in the caudate putamen, globus pallidus, 
STR, and substantia nigra (SN) (Aschner et al., 1999) and are clinically diagnosed as 
manganese intoxication or manganism.  Manganism is a severe, progressive and largely 
irreversible disorder that resembles, but is distinguishable from idiopathic Parkinson’s 
disease (PD) and other extrapyramidal motor disorders (Racette et al., 2012a).  
The prevailing symptoms of manganism include poor hand-eye coordination, 
bradykinesia, changes in mood and memory deficits, abnormal gait, muscle and joint pain 
or weakness, bent posture, and a kinetic tremor (Mergler, 1999; Racette et al., 2012a).  
These symptoms exist as a slowly progressing biphasic continuum, with psychiatric 
symptoms appearing first in the “prodromal period” or early phase of the disease, while 
motor symptoms dominate the later, “established” phase (Racette et al., 2012a; Rodier, 
1955) and persist even after the person is no longer exposed to Mn (Aschner et al., 2009; 
McMillian, 1999). 
Mn accumulation in the basal ganglia may alter levels of neurotransmitters, such 
as dopamine (DA) and GABA, in the striatum and in pathways postsynaptic to the 
nigrostriatal system (McMillian, 1999; Racette et al., 2012a) which produce the observed 
motor symptoms.  Data from rodent studies generally offer conflicting reports on how 




the effects of Mn on motor function is that hyperactivity is observed early in Mn toxicity, 
in both human and animal studies, and as the disease progresses, patients and animals 
both tend to become hypoactive.  
There is evidence that Mn exposure results in a Parkinson’s phenotype, with 
decreased dopamine in the striatum.  However, dopaminergic neurons in the substantia 
nigra and their terminals in the striatum, which are selectively lesioned in Parkinson’s 
disease, remain intact after Mn intoxication (Guilarte, 2010).  Thus, changes in 
neurotransmission, as opposed to frank cell-loss, likely underlie behavioral observations.  
Most studies to date have focused on striatal dopamine levels and not regional differences 
in other monoamines and their metabolites, or GABA.  Additionally, few studies have 
aimed to investigate changes in motor function in animals, particularly rodents, despite 
many of the prominent symptoms of manganism being motor deficits, including 
abnormal gait and postural impairment.  Therefore, the present study was undertaken to 
identify alterations in multiple neurotransmitter systems resulting from subchronic, low-
level Mn exposure in rats.  We have previously used a Mn exposure dose regimen, i.e., 6 
mg/kg i.p. injection for 4-6 weeks to study Mn toxicity on iron (Fe) and copper (Cu) 
transport properties in brain barrier systems (Zheng et al., 1999; Zheng et al., 2009). To 
ensure a dose-related response, the current study used two dose levels, 6 mg/kg and 15 
mg/kg, which bracket the commonly used doses to investigate changes in Mn levels with 
concomitant changes in regional neurochemistry, motor function, and changes at the 
cellular level.  Neurotransmitter levels were assessed in the striatum, substantia nigra, and 




hippocampus because many of the earliest symptoms of manganism are due to impaired 
memory.  Thus, examination of changes in 4 neurotransmitter (dopamine, 
norepinephrine, serotonin, and GABA) systems in multiple brain regions was expected to 
provide significant data on the complex neurochemical changes that result from Mn 
intoxication. 
 
3.3 Materials & Methods 
3.3.1 Chemicals 
All chemicals were of analytical grade, HPLC grade or the highest available 
pharmaceutical grade. HPLC grade water was obtained from a NANOpure Diamond 
Ultrapure Water System (Barnstead International, Dubuque, IA);  Mn chloride 
tetrahydrate (MnCl2·4H2O) from Fisher Chemical (Fair Lawn, NJ); nitric acid, 
tripotassium phosphate (K3PO4) and DPX mountant from VWR International (Radnor or 
West Chester, PA);   Mn, Cu, Zn, and Fe stock solutions from SCP Science (Champlain, 
NY); perchloric acid from RICCA (Arlington, TX); dopamine, 3,4-
dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 5-hydroxytryptamine 
(5-HT), 5-hydroxyindolacetic acid (5-HIAA), noradrenaline (NE), γ-aminobutyric acid 
(GABA) standards, disodium hydrogen phosphate, anhydrous (Na2HPO4) triethylamine 
(TEA), octanesulfonicacid (OSA), acetonitrile, paraformaldehyde (PFA), sodium 
phosphate monobasic (NaH2PO4), Triton X-100, and porcine skin gelatin from Sigma 




(Rockford, IL); methanol, ethylenediaminetetraacetic acid (EDTA), and sucrose from 
Macron Fine Chemicals (Center Valley, PA);  o-phthalaldehyde (OPA) from Pickering 
Laboratories (Mountain View, CA); and BCA protein assay kit from BioRad (Hercules, 
CA).  Normal donkey serum was purchased from Jackson ImmunoResearch (West 
Grove, PA); mouse monoclonal anti-TH and rabbit polyclonal anti-DARPP-32 antibodies 
from Millipore (Temecula, CA); secondary donkey anti-mouse IR800 and donkey anti-
rabbit IR800 antibodies from LICOR (Lincoln, NE); histoclear from National 
Diagnostics (Atlanta, GA); potassium permanganate from Amresco (Solon, OH); 
Fluorojade C from Histochem (Jefferson, AR); and glacial acetic acid from Mallinckrodt 
Chemicals (Phillipsburg, NJ). 
 
3.3.2 Animals 
Male Sprague Dawley rats were obtained from Harlan Laboratories, Inc. 
(Indianapolis, IN) and allowed to acclimate to the holding room for 7 days after arrival.  
Rats at time of experimentation were 8 weeks of age, weighing approximately 240-260g 
at study initiation.  Animals were randomized by drawing numbers for treatment 
designation.  Rats were group housed in a temperature- (72 ± 4 °C) and humidity- (30-
70%) controlled room on a 12 hour light/dark cycle (lights on at 0600).  Rats had ad 
libitum access to food (Harlan 2018 rodent diet) and reverse osmosis water.  
All animal studies were approved by the Institutional Animal Care and Use 





3.3.3 Mn Administration and Experimental Design 
According to Cooper (1984), doses of 5-20 mg/kg/d have not been shown to be 
very toxic in animal studies and therefore, our selected doses should not cause acute 
toxicity. The dose of 6 mg/kg was selected because it has been administered previously in 
our lab by multiple dose routes, including intravenous, oral, and intraperitoneal. With this 
dose, our lab has shown a significant reduction in both succinate dehydrogenase and 
aconitase (Zheng et al., 1999). 
Stock solutions of 6 mg Mn/ml (low dose) and 15 mg Mn/kg (high dose) were 
prepared by dissolving MnCl2·4H2O in saline and passing through a 0.2 µm syringe 
filter.  Mn-exposed rats received ip injections of either 6 mg Mn/kg or 15 mg Mn/kg in a 
volume of 1 ml/kg once per day, 5 days per week, for 4 consecutive weeks.  Control 
animals were administered the same volume of sterile saline.  
 
3.3.4 Sample Collection 
Animals were euthanized by decapitation 24 h after the last dose.  Brains were 
quickly removed from the skull and bisected midsagittally.  The left hemispheres were 
stored in 4% paraformaldehyde for histological evaluation.  The right hemispheres 
reserved for neurochemistry were placed in a coronal rat brain matrix and 2 mm slices 
containing the desired brain regions were obtained.  The samples were then further 
dissected on ice to obtain striatum, substantia nigra, and hippocampal samples, which 




determination of metal concentrations using atomic absorption spectroscopy (AAS).  
Samples were stored at -80°C until processing.  
  
3.3.5 Behavioral Testing 
On days 8, 11, and 18 of dosing, animal’s locomotor activity was evaluated using 
an open field behavioral test.  Animals were transferred to the behavioral testing room 
and placed inside an open field chamber.  The chambers were constructed of solid opaque 
Plexiglas measuring 40 cm × 40 cm.  Top Scan Lite computer software (version 2.0; 
Clever Sys Inc. Copyright 2000-2011) was used to generate a model of the open field 
chamber with accurate perimeter measurements and a center field comprising 60% of the 
total area.  Animals were placed in the open field chambers for 5 min and their positions 
were recorded by a camera mounted on the ceiling.  Behavioral testing conditions were 
simulated on two separate occasions during the first week of dosing to acclimate the 
animals to the testing environment.  Animals’ average velocities and distances traveled 
during the experiment were quantified using the Top Scan Lite software.  
 
3.3.6 Atomic Absorption Spectroscopy 
Liver and femur samples collected at necropsy were weighed on an analytical 
balance (AB204-S; Mettler Toledo, Columbus, OH) and transferred to a digestion vial.  A 
total volume of 2 ml nitric acid (HNO3) was added to each sample.  Tissues were 
digested in a high pressure MarsXpress microwave (CEM Corporation, Matthews, NC) 




with ddiH2O to 5 ml.  Each digestion solution was mixed thoroughly, transferred to a 15 
ml conical tube, sealed with parafilm, and stored at 4°C until analysis.  Hepatic and 
femur Mn, copper (Cu), zinc (Zn), and iron (Fe) concentrations were quantified using an 
Agilent Technologies 200 Series SpectraAA with GTA 120 graphite furnace (Santa 
Clara, CA).  Concentration ranges of standard solutions were between 1-10 ppb for Mn, 
1-50 ppb for Cu, 1-1.05 ppb for Zn, and 1-20 ppb for Fe. A 0.1% HNO3 blank was 
prepared and used to dilute metal standards at 1000 mg /l to appropriate working 
standards.  Samples were further diluted with ddiH2O to keep the readings within the 
concentration range of the standard curves.  The detection limit for Mn was 0.038 µg/l of 
the assay solution.  Metal content was expressed as µg/g of tissue.  
 
3.3.7 Neurochemical Analysis 
Neurotransmitter analysis was conducted similarly as previously described (Wang 
et al., 2013).  Briefly, STR, SN, and HP samples were frozen in liquid nitrogen at 
necropsy and stored at -80°C until processing.  Samples were sonicated in 0.5 ml 0.4N 
perchloric acid (HClO4) on ice, at 40% power, pulsing for 45 s to precipitate proteins.  
Samples were then centrifuged at 16,400 g for 35 min at 4°C. Supernatant was 
transferred to 0.22 µm Spin-X tube with nylon filter (Corning, Corning, NY) and 
centrifuged at 1000 g for 15 min at 4°C.  Samples were then stored at -80°C until HPLC 
analysis.  A Dionex UltiMate 3000 (ThermoScientific; Germering, Germany) system 
with a built in autosampler and a Coulochem III (Thermo Scientific) electrochemical 




as 5-HT and its metabolite 5-HIAA, NE, and GABA.  The optimized method used an 
isocratic monoamine mobile phase (consisting of 0.08 M NaH2PO4, 10% methanol, 2% 
acetonitrile, 2.0 mM OSA, 0.025 mM EDTA, and 0.2 mM TEA, in 13 mΩ purified 
water, pH 2.4).  Samples were injected and monoamines separated on a reverse phase 
C18 column (150 x 3.2mm, 3.0 μm particle size, MD-150, Thermo Scientific, 
Bannockburn, IL) protected by a guard column.  Separation occurred at 32 °C at a flow 
rate of 0.6 ml/min.  For GABA detection, samples were derivatized with OPA (o-
phthalaldehyde, methanol, and 2-mercaptoethanol) before injection onto the column.  The 
isocratic mobile phase (pH 6.75) consisted of Na2HPO4 in 13 mΩ purified water with 
22% methanol and 3.5% acetonitrile.  Separation occurred at 35°C with a flow rate of 0.5 
ml/min.  For monoamine neurotransmitter and metabolite detection, the electrochemical 
potential of the detector was set at 250 mV, with a conditioning cell at -150 mV.  For 
GABA detection, the electrochemical potential of the detector was set at 550 mV, with a 
conditioning cell at -150 mV.  Neurotransmitter and metabolite levels in each sample 
were quantified by comparing sample values to a reference curve prepared by adding 
standards of a known concentration to perchloric acid.  Chromeleon 7.0 software was 
used for data acquisition and analysis.  Neurotransmitter concentrations were expressed 
as ng/mg of protein as assessed by BCA protein assay (Smith et al., 1985) using BSA as 








At necropsy, the left hemisphere was immersed in 4% paraformaldehyde (PFA, 
catalog # P6148-500G; Sigma, St. Louis, MO) and post-fixed for 7 days at 4°C.  Then, 
hemispheres were stored in a 30% (w/v) sucrose (catalog # 8360-06; Macron Fine 
Chemicals, Center Valley, PA) solution until sinking.  The hemispheres were coronally 
sectioned in 30µm increments on a microtome (Microm HM450, Thermo Scientific; 
Walldorf, Germany) and sections were placed in cryoprotectant solution and stored at -
20°C until labeling.  Free-floating slices were rinsed 6 times with phosphate buffered 
saline (PBS), 10 min per rinse.  Sections were blocked in 10% normal donkey serum in 
PBST containing 0.3% Triton X-100 for 1 h.  Sections were incubated in primary 
antibody, either mouse monoclonal anti-TH (1:2000; cat. #MAB318; Millipore; 
Temecula, CA) or rabbit polyclonal anti-DARPP32 (1:500; cat.#AB10518; Millipore; 
Temecula, CA) diluted in PBST with 1% donkey serum for 72 h at 4°C.  Sections were 
rinsed 3 times with PBS and incubated with either donkey anti-mouse IR800 (1:500; 
cat.#926-32212; Li-Cor; Lincoln, NE) or donkey anti-rabbit IR800 (1:500; cat.#926-
32213; Li-Cor; Lincoln, NE) diluted in PBST with 1% donkey serum for 2 h at room 
temperature.  After 3 washes with PBS, sections were mounted on slides and air-dried 
overnight at room temperature.  After immersion in Histoclear for 10 min, slides were 
blotted dry and coverslipped with DPX mountant.  Immunofluorescence quantification 
was performed similar to previously described (Cannon et al., 2013; Tapias et al., 2014).  




(Li-Cor; Lincoln, NE) at 21µm resolution.  Regions of interest were selected and 
intensity of each region determined using Image Studio software (version 3.1).  
Another set of slices was processed for Fluorojade C staining to identify 
degenerating neurons.  Slices were removed from cryoprotectant and rinsed 6 times in 
PBS for 10 min per rinse.  Slices were mounted on slides coated with 0.5% porcine skin 
gelatin and dried overnight at room temperature.  Slides were then immersed for 5 min in 
0.03M tripotassium phosphate (K3PO4,) in 70% ethanol, diluted from 200% ethanol in 
water, and then rinsed in 70% ethanol and water for 2 min each.  Followed by immersion 
in a 0.06% potassium permanganate solution for 10 min and rinsed in water for 2 min.  
Slides were immersed in a 0.0001% Fluorojade C solution, diluted in 0.1% glacial acetic 
acid for 10 min followed by 3 rinses in water for 2 min each.  Slides were dried on a 
50°C heating block (Lab Line Instruments, Inc.; Melrose Park, IL) for 5 min and cleared 
in Histoclear for 1 min.  At this point, slides were blotted dry and coverslipped with DPX 
mountant.  All Fluorojade C staining steps were performed at room temperature.  
Negative control slices were treated in the same manner as all other slices, but primary 
antibody was omitted.  Slices from animals treated with kainic acid were used as a 
positive control (Sarkar & Schmued, 2011). Fluorescence was assessed on an Olympus 
(BX53F; Tokyo, Japan) microscope using a FITC filter and 50 ms pixel dwell time.  The 







3.3.9 Statistical Analysis 
All data are expressed as mean ± S.D. Statistical analyses of the differences 
between groups were carried out by one-way ANOVA. Where ANOVA analysis 
indicated that significant differences between groups occurred, specific differences were 
identified by post hoc analysis using Tukey’s test.  Statistical analysis of the behavioral 
data was done by one-way ANOVA with repeated measures.  A p-value less than 0.05 
was considered statistically significant.  All analyses were conducted using Graph Pad 
Prism (Version 3.0, Graph Pad Prism; San Diego, CA). 
 
3.4 Results 
3.4.1 Mn Exposure Reduces Body Weight 
 Animals were weighed daily prior to dose administration and weights recorded to 
the nearest 0.1 g (Fig. 9).  At the beginning of the study, there was no significant 
difference in body weights between groups (n=5 in all groups).  All animals weighed 252 
± 8 g. Mn treatment reduced animal’s body weight in a dose dependent manner.  Animals 
in the group receiving 6 mg Mn/kg lost an average of 10 g during the first three days of 
dosing and began to regain weight by the fourth day.  Animals in the group receiving 15 
mg Mn/kg lost an average of 40 g during the first five days of dosing and began to regain 
weight by the sixth day.  Although Mn-treated animals regained weight to some extent, 
average body weights were significantly lower than control beginning on the second day 




Noticeably, Mn dose administration by oral gavage at 50 mg/kg once daily, five 
days per week, for 6 weeks did not significantly reduce the body weight of Mn-treated 
animals compared with control animals; group averages at the end of the study were 
















Figure 9. Daily Intraperitoneal Injections of MnCl2 Resulted in Reduced Weight 
Gain among Mn-Exposed Animals. Rats were weighed prior to daily dose 
administration and weights were averaged for each group. Mn exposure resulted in 
significant changes in body weights in a dose-dependent manner. Control rats (square) 
consistently gained weight over the course of the study while animals in the low (6 
mg/kg; triangle) and high (15 mg/kg; inverted triangle) dose groups showed an initial 
decrease in body weight but began to gain weight after 3 and 5 days, respectively. Rats in 
the Mn-exposed groups continued to gain weight, but at significantly reduced rate 













3.4.2 Mn Accumulates in the STR and HP 
 AAS analysis was completed to determine if and to what extent Mn accumulated 
in brain tissue following Mn exposure. The levels of Mn in the STR and HP from both 

























Table 4. Concentration of Metal in Select Rat Brain Regions Following Subacute 
Mn Exposure. Atomic absorption spectroscopic analysis of Mn content in rat brain 
samples. Animals received i.p. injection of 6 or 15 mg/kg Mn once daily for 5 days per 
week for 4 weeks. Metal concentrations were quantified and are expressed as ug/g wet 
weight. Mn concentrations were significantly increased in the STR and HP of both Mn-
treated groups compared with controls. Data represent mean ± S.D., n-7-10; #p < 0.001. 
 
 6 mg Mn/kg as MnCl2 15 mg Mn/kg as MnCl2 
 STR HP STR HP 
Control 0.785 ± 0.229 0.642 ± 0.082 0.426 ± 0.164 0.337 ± 0.048 























3.4.3 Mn Exposure Resulted in Hypoactivity 
The average distance traveled decreased for animals in all groups between the 
first and the last training sessions (Fig. 10A).  The average velocities correspondingly 
decreased for each group (Fig. 10B). However, these changes did not reach statistical 
significance.  During the later training sessions, some animals exhibited long periods of 
inactivity in the testing chambers.  Examination of these two related behavioral 
parameters at each time point revealed significant decreases in distance traveled during 
the second and third behavioral testing sessions for the high dose group as compared with 
the control group (10.4 ± 2.42 vs. 19.4 ± 6.71, 7.6 ± 2.70 vs. 16.2 ± 1.30 m, respectively; 
mean ± S.D.; high dose vs. control; p < 0.05).  Additionally, the average velocity of the 
high dose group was significantly decreased compared to that of the control group during 
the third behavioral testing session (0.027 ± 0.011vs. 0.058 ± 0.002 m/s; mean ± S.D.; 
high dose vs. control; p < 0.05).  No significant differences were observed during the first 








Figure 10. Open Field Analysis of Locomotor Activity.  Distance traveled (A) and 
average velocity (B) were measured in an open field test on study days 8, 11, and 18.  
Animals were placed in the testing apparatus and behaviors measured for five minutes on 
each testing day.  Values for each group were averaged and are shown.  Distance traveled 
and average velocity were significantly reduced in both treatment groups compared with 
controls 8 days after Mn exposure began. These effects disappeared when animals were 
evaluated on study days 11 and 18. ANOVA with Tukey’s post hoc test.  Error bars 
represent S.D. (n = 3-5).  *: p < 0.05 for 6 mg/kg group compared with control; #: p < 




3.4.4 Levels of Biogenic Amines and Metabolites in Brain Tissue Following Mn 
Exposure 
 The DA level in the STR was significantly higher in the high-dose group than the 
control group (157.0 ± 15.73 vs. 99.8 ± 42.10 ng/mg protein; mean ± S.D.; high vs. 
control; p < 0.05; Fig. 11A).  DA levels in the SN and HP displayed a non-monotonic 
curve, with no statistical significances, where levels were decreased following 4 weeks of 
low-dose Mn treatment and were slightly higher in the high dose group, but not quite 
reaching the same levels as the control group (Fig. 11E,I). 
  Levels of the DA metabolite, DOPAC, in the STR of the high-dose group was 
significantly higher than those of the low-dose and control groups (10.7 ± 2.16, 16.9 ± 
1.68 vs. 10.6 ± 4.87 ng/mg protein; mean ± S.D.; low, high vs. control; p < 0.05 for both; 
Fig. 11B).  Levels of DA and DOPAC were similarly elevated in both the SN and HP, 
but these changes did not reach statistical significance (Fig. 11F,J). 
 Following 4 weeks of high-dose Mn exposure, levels of the secondary DA 
metabolite, HVA, were significantly higher in the STR compared with the low-dose and 
control groups (5.4 ± 1.58, 10.5 ± 1.79 vs. 2.7 ± 3.63 ng/mg protein; mean ± S.D.; low 
dose, high dose vs. control; p < 0.05 and  < 0.001, respectively; Fig. 11C).  HVA levels 
in the SN and HP were also significantly higher in the high-dose group than in the control 
group (in SN, 0.6 ± 0.29 vs. 0.3 ± 0.06 ng/mg protein; in HP, 0.2 ± 0.04 vs. 0.1 ± 0.02 




The DA turnover ratio was defined as the sum of the DA metabolites, DOPAC 
and HVA, divided by DA in each brain region.  While DA turnover in the STR appeared 
to be increased, differences were not significant (Fig. 11D).  In the SN, DA turnover was 
significantly increased for both Mn-treatment groups when compared with the control 
(1.5 ± 0.37, 1.6 ± 0.27 vs. 0.9 ± 0.22; mean ± S.D.; low, high vs. control; p < 0.05 for 
both; Fig. 11H).  There was no difference between the turnover ratios of the low- and 
high-dose groups.  In the HP, differences in DA turnover did not reach statistical 















Figure 11.  HPLC Analysis of Dopamine, its Metabolites, and Turnover.  DA 
(A,E,I), and its metabolites 3,4-dihydrophenylacetic acid (DOPAC; B,F,J), and 
homovanillic acid (HVA; C,G,K) were quantified in STR (A-C), SN (E-G), and HP (I-
K) by HPLC with electrochemical detection.  DA turnover in each region was calculated 
as the sum of the metabolites divided by DA concentration (D,H,L).  ANOVA with 
Tukey’s post hoc test.  Data represent mean ± S.D. (ng/mg protein; n = 3-5).  *: p < 0.05, 









 5-HT levels in the STR and SN were not significantly changed following either 
Mn-treatment as compared with the control (Fig. 12A,D).  In the HP, levels of 5-HT 
revealed a non-monotonic curve, decreasing in the low-dose but increasing in the high-
dose group, in comparison with the control group.  The level of 5-HT in the HP was 
significantly higher in the high-dose treatment group than in the low-dose group (3.2 ± 
0.80 vs. 1.9 ± 0.20 ng/mg protein; mean ± S.D.; high dose vs. low dose; p < 0.01; Fig. 
12G). 
 Significantly elevated levels of the 5-HT metabolite, 5-HIAA, were observed in 
the STR of the high-dose group, when compared with the low-dose group (4.7 ± 0.58 vs. 
3.3 ± 0.47 ng/mg protein; mean ± S.D.; high dose vs. low dose; p < 0.05; Fig. 12B).  Mn 
exposure did not affect the level of 5-HIAA in the SN or HP (Fig. 12E,H).   
The 5-HT turnover ratio is defined as the amount of 5-HIAA divided by 5-HT in 
each brain region.  5-HT turnover was not statistically changed in the three brain regions 









Figure 12.  HPLC Analysis of Serotonin, its Metabolite, and Turnover.  5-HT 
(A,D,G) and its metabolite 5-HIAA (B,E,H) were quantified using HPLC with 
electrochemical detection.  5-HT turnover was calculated by dividing the concentration of 
5-HIAA by 5-HT (C,F,I). ANOVA with Tukey’s post hoc test.  Data represent mean ± 







NE levels in the STR and SN were not significantly different between Mn 
exposed and control animals (Fig. 13A-B).  In the HP, significantly higher NE levels 
were observed in the high-dose exposure group compared with the low-dose group (6.4 ± 
















Figure 13. HPLC Analysis of Norepinephrine Levels.  NE levels in striatum (STR) 
(A), substantia nigra (SN) (B), and hippocampus (HP) (C) were quantified using HPLC 
with electrochemical detection.  ANOVA with Tukey’s post hoc test for multiple 














Levels of GABA, the main inhibitory neurotransmitter, were not statistically 
different in the STR or SN (Fig. 14A-B).  A significant increase in the HP GABA level 
was observed in high-dose Mn exposed animals compared with controls (2,221 ± 310.4 
















Figure 14. HPLC Analysis of GABA Levels.  GABA levels in striatum (STR) (A), 
substantia nigra (SN) (B), and hippocampus (HP) (C) were quantified using HPLC with 
electrochemical detection.  ANOVA with Tukey’s post hoc test for multiple comparisons.  














3.4.5 Immunohistochemistry of Striatum Following Mn Exposure 
 Fluorescence intensities of TH and DARPP-32 were not statistically different in 
the STR of Mn-exposed animals in comparison with those of control animals (Fig. 15C 















Figure 15.  Quantitative Infrared Immunofluorescence Analysis of Striatal TH.  
Coronal slices from rat striatum (STR) were probed for antibodies against TH.  
Secondary antibodies were tagged with an infrared fluorescent marker.  Depicted are 
representative scans showing fluorescence intensity in STR slices from control animals 
(A) and Mn treated animals (B).  Manually selected ROIs are shown as dashed lines.  A 
minimum of three slices were quantified from each animal and the resulting values were 
averaged.  Group values were averaged and are shown (C).  No difference was observed 
between control and either low or high dose groups.  Mn treatment did not affect STR TH 
signal intensity.  ANOVA with Tukey’s post hoc test for multiple comparisons. Data 










Figure 16.  Quantitative Infrared Immunofluorescence Analysis of Striatal 
DARPP32.  Coronal slices from rat striatum (STR) were probed for antibodies against 
DARPP32.  Secondary antibodies were tagged with an infrared fluorescent marker.  
Depicted are representative scans showing fluorescence intensity in striatal slices from 
control animals (A) and Mn treated animals (B).  A minimum of three slices were 
quantified from each animal and the resulting values were averaged.  Group values were 
averaged and are shown (C).  No difference was observed between control and either low 
or high dose groups.  Mn treatment did not affect striatal DARPP32 signal intensity.  
ANOVA with Tukey’s post hoc test for multiple comparisons. Data represent mean ± 













The data presented in the current study have established that subchronic, low-
doses of MnCl2 significantly altered levels of neurotransmitters in rats and produces a 
dose-dependent decrease in locomotor behaviors.  
The low dose Mn treatment used in this study has been detailed in a previous 
report from our laboratory and others (Lebda et al., 2012; Zheng et al., 2009). The high 
dose level of Mn used in this paper has been used by several other laboratories (Ou et al., 
2011; Hong et al., 1984; Husain et al., 2001). Under these dose regimens, Mn exposure 
significantly reduced animals’ body weights. Additionally, Mn treatment at the high dose 
markedly reduced motor activity. 
In a review of Mn exposed animal models, McMillian (1999) noted that 
behavioral results from many studies show a “slowly developing biphasic response to Mn 
exposure,” with an initial increase in the observed behavior followed by a subsequent 
decline in behavior.  This is true for multiple species, including rats and monkeys 
(Nachtman et al., 1986; Vezér et al., 2007). However, in the current study, we did not 
observe the initial increase in motor activity. This could be due to a late first time point 
that may miss the early behavioral changes.  An alternative hypothesis is that our animals 
were at the tail end of the early, prodromal phase.  As such, the observed hypoactivity 
may have resulted from altered neurochemistry and progression of the treatments’ effects.  
Our HPLC results clearly demonstrated that DA levels in STR, but not in SN, 




observed in our study is consistent with reports in the literature that at lower internal 
cumulative doses of Mn exposure, there is a trend towards increasing DA levels in the 
STR (reviewed by Gwiazda et al., 2007).  Our dose levels were within the range they 
reviewed and our findings were in agreement with their conclusions.  
We have also observed significantly increased levels of HVA in the STR; but 
increases in NE were limited to the HP. Increased levels of HVA and NE in the STR have 
been observed in studies with dose duration from 90-120 days (Chandra et al., 1979).  
Species differences between the two studies (i.e. mice vs. rats) may account for the 
discrepancy noted.  While there is a report to suggest increased GABA in the STR for a 
wide range of Mn doses (Gwiazda et al., 2007), we did not observe significant changes in 
striatal GABA, but did find significantly increased levels of GABA in the HP of Mn-
treated rats. In the SN, GABA levels were unchanged. 
Several reports have demonstrated that Mn treatment initially causes an increase 
in DA, HVA, and NE, but as the exposure increases, the neurotransmitter levels are 
decreased (Chandra et al., 1979; Chandra & Shukla, 1981; Cotzias et al., 1974).  It was 
proposed that DA and NE are increased due to increased synthesis of biogenic amines 
early in manganism (Chandra et al., 1979).  Our data are in close agreement with this 
hypothesis.  Several mechanisms may potentially explain the findings in this study.  First, 
the increased levels of the enzyme MAO-B may metabolize DA to DOPAC. Gwizada et 
al. (2007) noted increased MAO-B levels after low doses of Mn and they also showed 
increased striatal DA, in agreement with our results.  Our DA turnover results further 




neurons may have an impaired ability release DA into the synapse after Mn exposure, 
which could cause intracellular DA levels to increase. Calabresi et al. (2001) postulated 
that altered release characteristics may alter the life-time of DA within the STR. Finally, 
it is plausible that Mn may stimulate TH activity to increase DA production (Chandra et 
al., 1979).  In this study, we have assessed levels of TH in the STR of all groups of rats 
by immunofluorescence; however, the striatal TH expression was not affected by Mn 
exposure. Thus, it is unlikely that the increases in DA levels were attributable to Mn 
action on TH. In future studies, it may be prudent to investigate changes of TH levels in 
SN, because DA is primarily synthesized in the SN and axons project to the STR (Kunar 
et al., 1999). 
It must be noted that differences in Mn species, dose routes, durations and 
frequencies used may yield different results due to the complex effects of Mn (Ordoñez-
Librado et al., 2008).  For example, a similar study by Blecharz-Klin, et al. (2012) used 
an intranasal dose route for two weeks instead of four in slightly older animals; they did 
not observe a difference in either striatal DA or DOPAC, but noted a decreased level of 
striatal HVA.  Additionally, they observed decreased DA turnover.  It is possible that 
different dose regimens may exert marked differences in neurochemical changes.  
Our recent X-ray fluorescence imaging data show that Mn accumulates in the SN 
(Robison et al., 2012). However, the current neurochemistry study showed that the SN 
appears to be largely unaffected by Mn treatment.  We noted altered levels of HVA in the 
SN, but the region was unaffected for all other neurotransmitters investigated.  These SN 




It is worth noting that there has been significant effort devoted to examining a 
potential role that Mn exposure may play in PD.  The observation of increased DA is in 
contrast to a key feature of PD, which is striatal DA depletion due to loss of nigrostriatal 
DA neurons.  Chronic Mn-induced increases in DA could be deleterious as DA itself is a 
reactive molecule contributing to oxidative stress (Hastings & Zigmond, 1994).  Finally, 
PD is characterized by complex neurochemical changes, beyond striatal DA depletion 
alone. Even in a straightforward animal model involving chemical ablation of 
nigrostriatal DA neurons, complex changes occur in other neurotransmitter systems 
(Schwarting & Huston, 1996).  Thus, elucidating similarities and differences between Mn 
treatment and prominent PD models will require additional studies. 
In summary, our neurochemistry data are in agreement with existing data in the 
literature, suggesting that this dose regimen produces a model of early manganism. 
Because the symptoms of manganism are slowly progressive and exist along a 
continuum, perhaps this model is nearer the end of the first phase.  Use of this model of 
early manganism may allow the study of mechanisms that progress to clinical 
manganism. Cotzias (1958) noted that the early phase may lack motor disturbances and 
the disease primarily consists of psychological symptoms.  These psychological 
symptoms are harder to detect and therefore, more sophisticated behavioral analyses to 





CHAPTER 4: MANGANESE INTERACTION WITH BRAIN REPAIR 






 Manganese (Mn) is necessary for normal biological processes; however, 
overexposure to this metal can lead to toxic accumulation in the body, particularly in the 
brain. Mn accumulation in the brain can result in altered copper (Cu) homeostasis. 
Altered Cu levels are implicated in a variety of neurodegenerative disease pathologies. 
The goal of this study was to test the hypothesis that Mn accumulation in the rat 
subventricular zone (SVZ) led to altered neurogenesis as a result of altered Cu 
homeostasis in this region. Adult male rats were intranasally exposed to Mn daily for two 
weeks. During the last four days of Mn administration, rats also received twice daily 
injections of BrdU to label actively proliferating cells in the SVZ. Brain slices from these 
animals were used for immunohistochemistry studies and triple labeled for BrdU and 
DCX (neuroblasts), and GFAP (stem cells) to distinguish between newly differentiated 
cell types. Following Mn exposure, Mn concentrations were significantly increased and 




BrdU and DCX expression were significantly increased in the SVZ as well as the 
olfactory bulb while GFAP was only significantly increased in the SVZ. The results of 
this study demonstrate that Mn exposure affects adult neurogenesis by altering Cu 
homeostasis in the SVZ. This suggests that Mn exposure may negatively impact those 
neurodegenerative diseases which implicate Cu in their pathology. 
 
4.2 Introduction 
 Exposure to high levels of the essential metal manganese (Mn) is neurotoxic, 
resulting in manganism, an irreversible neurological disease with symptoms similar to, 
but distinguishable from idiopathic Parkinson’s disease. Excess exposure predominantly 
occurs via inhalation in occupational settings, which is not surprising because Mn is one 
of the most commonly used metals in industrial processes. It is used both as a pure metal 
and an alloy to produce a variety of products including dry-cell batteries, glass and 
ceramics (Nadaska, Lesny, and Michalik, 2012). The median onset of disease is 1 year 
after exposures begin and includes both motor and behavioral symptoms (Racette et al., 
2012a). Motor symptoms are exclusively attributed to accumulation of Mn in the basal 
ganglia (Newland, 1999). 
 In our lab, we have confirmed that Mn accumulates in the rodent basal ganglia 
and other brain regions, with considerable accumulation in the subventricular zone (SVZ) 
and the hippocampus (HP); the latter has the structure called the subgranular zone (SGZ) 
in the dentate gyrus. The SVZ and SGZ are important in adult neurogenesis because these 
are the only two recognized neurogenic niches in the adult mammalian brain. These 




dividing, undifferentiated neural stem progenitor cells (Garzon-Muvdi and Quinones-
Hinojosa, 2010). The neurogenic capability of the SVZ is due in part to its proximity to 
nutrients and growth factors in the cerebrospinal fluid (CSF) filling the lateral ventricles 
where the SVZ is located (Curtis, Faull and Eriksson, 2007). In the SVZ, there are four 
cell types: the ependymal cells “type E” cells, “type B” cells which are astrocytic stem 
cells (ASCs; GFAP+ astrocytes) and give rise to “type C” (nestin+ transit-amplifying) 
cells, which finally differentiate into “type A” neuroblasts (DCX+) (Doetsch et al., 1999; 
Zaverucha-do-Valle et al., 2013). The neuroblasts migrate anteriorly along the rostral 
migratory stream (RMS) to the olfactory bulb (OB) where they may mature into local 
interneurons. Surviving cells are able to functionally integrate, replacing dead cells of the 
same phenotype. It has been suggested that functionally integrated new neurons 
participate in neural plasticity, learning and memory, as well as sexual behaviors in 
mammals, and song production in birds (Alvarez-Buylla and Garcia Verdugo, 2002). 
 The cells in the SVZ can be stimulated by neurodegenerative diseases, such as 
Huntington’s disease, and also epilepsy and stroke (Curtis, Faull and Eriksson, 2007) or 
Mn exposure (Fu et al., 2015; Wang et al., 2012). In our lab, we have shown that Mn 
exposure by subchronic intraperitoneal injection induces cell proliferation in the SVZ. 
Further, we have investigated changes in cell differentiation after Mn exposure and 
showed increased production of glial cells.  
 Mn accumulates in the striatum (STR), hippocampus (HP), and substantia nigra 
(SN), brain regions implicated in clinical manganism, as well as the SVZ. In the SVZ, we 
also observed a significant reduction in copper (Cu) levels after Mn treatment (Fu et al., 




region are about 20-30 times higher than in other brain structures (Pushkar et al., 2013), a 
finding our lab has confirmed using atomic absorption spectroscopy (AAS). These 
findings suggest that high Cu levels in the SVZ are required to maintain the normal status 
of neurogenesis in adult brains, and that Mn exposure alters Cu homeostasis in the SVZ. 
Cu dyshomeostasis in the brain is implicated in the pathology of a number of 
neurodegenerative diseases, including idiopathic Parkinson’s disease, Alzheimer’s 
disease, familial amyotrophic lateral sclerosis, prion disease, Wilson’s disease and 
Menkes’ disease (Barnham and Bush, 2008, Gaggelli et al., 2006, Mates et al., 2010, 
Zheng and Monnot, 2012).  
Previous in vivo studies of adult neurogenesis have investigated the effects of Mn 
exposure via intraperitoneal, intravenous, or oral gavage administration of Mn-containing 
solutions (Fu et al., 2015; Kikuchihara et al., 2015). However, the primary route of toxic 
Mn exposure in the human population is inhalation, which permits a direct pathway from 
the environment into the central nervous system (CNS). This route is of particular 
relevance to adult neurogenesis studies because direct transport along the olfactory 
pathway would ensure the highest concentration of Mn reached the OB. Retrograde 
transport of Mn from the OB along the RMS would potentially deliver higher 
concentrations of Mn to the SVZ than any other route of exposure.  
The present studies used an intranasal instillation (IN) technique to study the 
effects of Mn exposure on adult neurogenesis. The goals of this study were: (1) to 
identify the changes in adult neurogenesis resulting from Mn exposure, (2) to determine 
the extent of metal dysregulation after Mn exposure, and (3) to establish IN as a valuable 




rats. The results of these studies are expected to provide direct evidence of Mn interaction 
with neuronal repair mechanisms by altering Cu homeostasis. These results are likely to 
create a new area of toxicology research, specifically metals and neurotoxicological 
research. 
 
4.3 Materials and Methods 
 
4.3.1 Experimental Design and Animals 
Male Sprague Dawley rats were obtained from Harlan Laboratories, Inc. 
(Indianapolis, IN) and allowed to acclimate to the test facility for 7 days. When the study 
commenced, animals were 8 weeks old and weighed approximately 180-200 g. Rats were 
group housed in a temperature- (72 ± 4 °C) and humidity- (30-70%) controlled room on a 
12 hour light/dark cycle (lights on at 0600).  Rats had ad libitum access to food (Harlan 
2018 rodent diet) and reverse osmosis water.  
Rats were weighed each day prior to dose administration. At the time of 
experimentation, rats received an IN of saline (as control), 0.2, or 0.8 mg Mn/kg as 
MnCl2 daily for 14 days. These doses were chosen based on the work by Blecharz-Klin 
et al., (2012) who showed altered neurochemistry and behavior following this regimen. 
During the last 4 days of Mn administration, rats also received twice daily intraperitoneal 
injections of 50 mg BrdU/kg. BrdU is a thymidine analog that is incorporated into the 
DNA of actively dividing cells during the S phase of the cell cycle. Animals’ final body 




See Figure 17 for a diagram of the overall experimental design. All animal studies were 







































Figure 17: Chapter 4 Experimental Design. Shows daily Mn instillations, BrdU 































4.3.2 Intranasal Instillation Technique 
Prior to Mn administration, rats were anesthetized using 2% isoflurane gas. A 
Hamilton syringe coupled to a length of flexible polyethylene tubing (0.18 mm inner 
diameter) was filled with the dose solution to be instilled. The tubing was inserted 
approximately 2 cm into the rat’s nostril and 10 µL of solution was instilled at the 
olfactory mucosa (see Figure 18). The tubing was removed and the procedure repeated in 
the other nostril; the starting side alternated each day (Genter et al., 2012). The intranasal 
instillation method has previously been used to study Mn exposure by many researchers, 


























Figure 18: Diagram of Intranasal Instillation Procedure. Blue line indicates path of 
flexible tubing into rodent nasal passage. Dose solutions are instilled at the olfactory 
mucosa (OM) and Mn passes primary neurons by retrograde transport directly into the 





























4.3.3 Euthanasia and Necropsy 
Rats were deeply anesthetized by intraperitoneal injection with a 
ketamine/xylazine cocktail (75/10 mg/kg) and exsanguinated. Rats used for 
immunohistochemistry studies were perfused with phosphate buffered saline, pH 7.4 
(PBS) followed by 4% paraformaldehyde to fix the tissues. The whole brain was removed 
and postfixed in 4% paraformaldehyde at 4°C. Rats used for all other studies were not 
perfused. From these animals, blood samples were collected from the descending aorta 
into heparinized vials. Brains were removed and the SVZ, STR, HP, OB, choroid plexus, 
pituitary, thalamus and frontal cortex tissues were dissected on ice. Lung tissue and 
femurs were also collected. All tissues were stored at -80°C until processed. Blood was 
not stored; it was processed for plasma 20 min after collection.  
 
4.3.4 Atomic Absorption Spectroscopy 
Tissue samples collected at necropsy were weighed then digested in enough 
concentrated nitric acid (HNO3) to completely cover the tissues. Digestion was facilitated 
by using a high pressure MarsXpress microwave (CEM Corporation, Matthews, NC) for 
15 min at 200°C.  SVZ, CP, and pituitary tissues were digested in acid overnight in an 
oven at 55°C. Each digestion was diluted with ddiH2O to keep the readings within the 
ranges of the standard curves: 1-10 ppb for Mn and 1-50 ppb for Cu. Tissue metal 
concentrations were quantified using an Agilent Technologies 200 Series SpectrAA with 





4.3.5 Western Blotting 
Total protein was isolated from each brain region. Tissues were lysed in RIPA 
homogenization buffer, minced with spring scissors, and then sonicated. Tissues were 
incubated on ice for 10 min and centrifuged at 12,000 x g for 15 min at 4°C. Supernatant 
was collected and protein was denatured by boiling for 5 min at 95°C. Pierce BCA 
Protein Assay (ThermoFisher) was used to quantify protein. Approximately 50 µg of total 
protein was loaded per lane and separated on a 10-15% SDS-polyacrylamide gel then 
blotted onto a polyvinylidene membrane using a semi-dry transfer (BioRad).  
The membrane was blocked in 5% non-fat dry milk diluted in a solution of Tris-
buffered saline solution with 0.01% Tween 20 pH 7.4 (TBST) for 2 hr at room 
temperature. The membrane was incubated overnight at 4°C with primary rabbit anti-Ctr1 
antibody (43 kDa; 1:2,000) in blocking solution diluted 1:5 in TBST. To detect the 
primary antibodies, membranes were incubated for 2 hr at room temperature in a solution 
containing horseradish peroxidase-conjugated secondary anti-rabbit antibody (1:3,000). 
The signals were visualized using enzyme chemiluminescent solutions. Membranes were 
rinsed in TBST and stripped in stripping buffer for 20 min then rinsed again. The 
blocking procedure was repeated. The primary antibody solution contained mouse anti-β-
actin (42 kDa; 1:5,000) and the secondary antibody solution contained horseradish 
peroxidase-conjugated anti-mouse antibody (1:10,000). Each blot was performed in 
triplicate.  
For α-synuclein and Iba1 blotting, the membrane was blocked in Li-Cor blocking 
solution (Li-Cor). The membrane was incubated overnight at 4°C in a primary antibody 




kDa; 1:1,000) and chicken anti-β-actin (42 kDa; 1:3,000) in TBST. To detect the primary 
antibodies, membranes were incubated for 2 hr at room temperature in TBST containing 
infrared-linked secondary antibodies donkey anti-mouse (Li-Cor, IR800; 1:20,000), 
donkey anti-rabbit (Li-Cor, IR800; 1:20,000) or donkey anti-chicken (Li-Cor, IR680; 
1:20,000). The blots were imaged with the Odyssey infrared imaging system (Li-Cor) at 
84 µm resolution with medium intensity and quantified with Image Studio software 
(version 3.1). Each blot was performed in triplicate. 
 
4.3.6 qPCR Analysis of Dmt1 and Ctr1 mRNA  
Total RNA was isolated from tissues using TRIzol reagent following the 
manufacturer’s instructions. RNA samples were reverse-transcribed using the BioRad 
iScript cDNA synthesis kit (Hercules, CA).  The iTaq Universal SYBR Green Supermix 
was used for qPCR analyses following the manufacturer’s instructions.   
Dmt1 cDNA was amplified using the following nucleotide sequences:  
Forward primer: 5’-GAT TCC AGA CGA TGG TGC TT-3’  
Reverse primer: 5’- GTG AAG GCC CAG AGT TTA CG -3’ 
Ctr1 cDNA was amplified using the following nucleotide sequences: 
Forward primer: 5’-ACC TTT GCG CTG ACT CTC AT-3’  
Reverse primer: 5’- TGA TCG ATC TCC ATG TGG TT -3’ 
β-actin was used as an internal control with the following sequences: 
 Forward primer: 5’- AGC CAT GTA CGT AGC CAT CC -3’ 




Primers were designed using the Primer Express 3.0 software.  All primers were 
obtained from Integrated DNA Technologies.  Experimental conditions were optimized 
for annealing temperature, primer specificity, and amplification efficiency.  The 
amplification was performed in the CFX ConnectTM quantitative Real-Time PCR 
Detection (qPCR) system (BioRad, Hercules, CA) with an initial 3 min denaturation at 
95oC followed by 40 cycles of 30 sec denaturation at 95oC, 10 sec gradient from 55.0 to 
65.0oC and a 30 sec extension at 72oC.  A dissociation curve was used to verify that the 
majority of fluorescence detected could be correlated to the labeling of specific PCR 
products, and to verify the absence of primer dimers and sample contamination.  Each 
qPCR reaction was run in triplicate.  Relative mRNA expression ratios between groups 
were calculated using the delta-delta cycle time (ΔΔCt) formulation; Ct is the threshold 
cycle time value.  Ct values of Dmt1 and Ctr1 were normalized to the reference gene in 
the same sample.  The relative ratio between control and treatment groups was then 
calculated and expressed as relative increases, setting the control as 100% following the 
method of Livak and Schmittgen (2001).   
4.3.7 Biogenic Amine Quantification 
Neurotransmitter analysis was conducted as previously described (O’Neal et al., 
2014b; Wang et al., 2013).  Briefly, OB and thalamus samples were sonicated in 0.5 ml 
0.1N perchloric acid (HClO4) on ice, at 50% power, pulsing for 45 s to precipitate 
proteins.  Samples were then centrifuged at 16,400 x g for 35 min at 4°C. Supernatant 
was transferred to 0.22 µm Spin-X tube with nylon filter (Corning) and centrifuged at 
1000 x g for 15 min at 4°C.  Prepared samples were then stored at -80°C until HPLC 




with a built in autosampler and a Coulochem III (Thermo Scientific) electrochemical 
detector were used for HPLC analysis of DA, its metabolites DOPAC and HVA, as well 
as 5-HT and its metabolite 5-HIAA, NE, GABA, glutamate, and taurine.  The optimized 
monoamine method used an isocratic mobile phase (consisting of 0.08 M NaH2PO4, 10% 
methanol, 2.0 mM OSA, 0.025 mM EDTA, and 0.2 mM TEA, in 13 mΩ purified water, 
pH 2.4).  Samples were injected and monoamines separated on a reverse phase C18 
column (150 x 3.2mm, 3.0 μm particle size, MD-150, Thermo Scientific, Bannockburn, 
IL) protected by a guard column.  Separation occurred at 32 °C at a flow rate of 0.6 
ml/min.  For GABA, glutamate, and taurine detection, samples were first derivatized with 
OPA (o-phthalaldehyde, methanol, and 2-mercaptoethanol) before injection onto the 
column.  The isocratic mobile phase (pH 6.75) consisted of Na2HPO4 in 13 mΩ purified 
water with 22% methanol and 4% acetonitrile.  Separation occurred at 35°C with a flow 
rate of 0.5 ml/min.  For monoamine neurotransmitter and metabolite detection, the 
electrochemical potential of the detector was set at 250 mV, with a conditioning cell at -
150 mV.  For GABA, glutamate, and taurine detection, the electrochemical potential of 
the detector was set at 550 mV, with a conditioning cell at -150 mV.  Neurotransmitter 
and metabolite levels in each sample were quantified by comparing sample values to a 
reference curve prepared by adding standards of a known concentration to perchloric 
acid.  A sample chromatogram displaying the results for GABA, glutamate, and taurine is 
shown in Figure 19. Chromeleon 7.0 software was used for data acquisition and analysis.  
Neurotransmitter concentrations were expressed as ng/mg of protein as assessed by BCA 









Figure 19. Sample HPLC Chromatogram. Analysis of olfactory bulb tissue from a 
control animal showing separated peaks identified as GABA, glutamate, and taurine. 






















4.3.8 BrdU/DCX/GFAP Triple Imaging in Brain Sections 
Brains were transferred from 4% paraformaldehyde after 7 days to a 30% sucrose 
solution for 7 days to equilibrate tissue, preventing the formation of ice crystals during 
freezing. Frozen brains were cut (30 µm thickness) on a microtome and stored in 
cryoprotectant at -20°C. Every 6th section (180 µm interval) throughout the SVZ and 
SGZ was used for IHC. During processing, sections were removed from cryoprotectant 
and floating slices were triple-rinsed in PBS x 10 min (rinsed). Sections were incubated 
in 2M HCl for 2 hr to denature DNA then rinsed. Denatured slices were blocked in PBS 
containing 0.5% Triton X-100 (v/v), 5% BSA, and 10% normal goat serum for 1.5 hr at 
room temperature and then rinsed. Rinsed sections were incubated overnight at 4°C with 
mouse anti-BrdU (1:400), rabbit anti-DCX (1:1,000), chicken anti-GFAP (1:1,000) 
primary antibody in blocking solution diluted 1:10 with PBS. The sections were rinsed 
and incubated for 2 hr at room temperature with goat anti-mouse (488 nm; 1:1,000), goat 
anti-rabbit (555 nm; 1:1,000), and goat anti-chicken (638 nm; 1:1,000) secondary 
antibody in dilute blocking solution. Labeled sections were rinsed for 15 min and 
mounted on charged slides then coverslipped in ProLong Gold antifade solution 
(Molecular Probes). Slides were protected from light and allowed to dry overnight at 
room temperature. BrdU, DCX and GFAP immunofluorescence were visualized in the 
same sections using a Nikon inverted confocal laser scanning microscope. Images of the 
SVZ and OB were taken from each slice at 40X (Nikon; Plan Apo, 4X/0.20 ∞ 0.17) and 
x100 (Nikon; Plan Apo, 10X/0.45 ∞ 0.17) magnifications. Images of the SVZ were also 
taken from each slice at x400 (Nikon; Plan Apo, 40X/0.95 ∞ 0.17) magnification. Images 




image, the frame average of 16 images was obtained to improve the signal to noise ratio.  
Signal intensities were quantified using the NIS-Elements BR (Version 3.10) program.  
The software automatically detected regions of interest (ROIs) and calculated mean 
intensity values. A minimum of four to six slices per animal were imaged and the values 
averaged to produce one value per animal. The group averages were used for statistical 
analysis.  
 
4.3.9 Statistical Analysis 
All data are expressed as mean ± S.D. Statistical analyses of the differences 
between three treatment groups were carried out by one-way ANOVA. Where ANOVA 
analysis indicated significant differences between groups, specific differences were 
identified by post hoc analysis using Tukey’s test.  Analyses of differences between two 
treatment groups were carried out by Student’s t test. Group differences were considered 
statistically significant for p-values less than 0.05.  All analyses were conducted using 
SPSS (Version 21.0). 
 
4.4 Results 
4.4.1 Body and Relative Organ Weights Following Mn Exposure 
 Animals’ body weights were recorded daily throughout the 15-day study. Control 
animals showed steady weight gain over the course of the study; final body weights were 
272.6 ± 9.2 (mean ± S.D.) as compared to 188.8 ± 6.7 on study day 1. Comparatively, 
animals instilled with 0.2 mg/kg and 0.8 mg/kg (cumulative Mn dose ranged from 2.8-




compared with control animals’ final body weights. In previous experiments utilizing 
different Mn exposure routes, animals receiving intraperitoneal exposure showed 3.1-
12.0% reduction in body weight gain (cumulative dose range 120-300 mg/kg) compared 
with controls (Chapter 3) and animals orally exposed (cumulative dose 1,500 mg/kg) 
showed a 5.3% reduction in body weight gain compared with controls (Chapter 2).  
 For animals instilled with Mn, relative organ weights of the spleen and pituitary 
gland were also calculated as: 
 
Relative organ weights were calculated as a crude estimate to determine if 
systemic toxicity or immune responses occurred as a result of intranasal Mn exposure. 
The spleen and pituitary glands were selected for examination because they play a role in 
immune function and their sizes may vary during an immune response. Additionally, the 
spleen and pituitary gland have readily distinguishable boundaries which facilitated 
collection at necropsy. Comparing the whole organ weights to the animals’ final body 
weights revealed that relative organ weights of neither spleen, nor pituitary was 
significantly altered following Mn exposure (p=0.74 and p=0.63, respectively). Finally, 
whole brain weight was unchanged following intranasal Mn exposure (p=0.08). 
 
4.4.2 Metal Concentrations in Brain and Body Tissues 
 AAS analysis of select tissues in the brain revealed that Mn concentrations were 
significantly increased following Mn instillation of either 0.2 or 0.8 mg/kg in all regions 




instillation, Mn concentrations in the brain were highest in the olfactory bulb (2.33 ± 1.86 
µg/g). Interestingly, the SVZ had the second highest Mn concentration, which was 
significantly increased by 95.5% following Mn exposure (1.29 ± 0.45 µg/g for the 0.8 
mg/kg dose group compared with the control group (0.66 ± 0.31 µg/g; p < 0.01).  
 Cu concentrations were differentially affected in brain regions following Mn 
exposure (Table 6). In the STR, Cu concentrations were significantly increased following 
Mn exposure (4.98 ± 0.56 µg/g compared with 2.57 ± 0.35 µg/g for controls; p < 0.01). 
In the SVZ, Cu concentrations were significantly reduced between 46.4%-86.7% 
following Mn exposure (5.17 ± 0.78 µg/g and 1.28 ± 0.04 µg/g for 0.2 mg/kg and 0.8 
mg/kg, respectively, compared with 9.64 ± 2.81 µg/g in controls; p < 0.01). The SVZ was 
the only tissue examined in which Cu concentration was significantly reduced following 
Mn exposure. In the majority of tissues analyzed, including the olfactory bulb, 
hippocampus, frontal cortex, and cerebellum, Cu concentrations remained unchanged. It 
is also interesting to note that basal Cu concentration is highest in the SVZ, about 3.75-
fold higher than in the STR or 3.4-fold higher than HP Cu concentrations. This confirmed 
the previous findings from synchrotron analysis of SVZ that the basal Cu concentration 











Table 5. Tissue Mn Concentrations Were Analyzed by Atomic Absorption 
Spectroscopy Following Intranasal Mn Exposure. Data represent mean ± S.D. µg/g; 
n=4-10; *p < 0.05, **p < 0.01, ***p < 0.001 when compared with controls.  
 
Mn Levels 
Tissue control 0.2 mg/kg 0.8 mg/kg 
SVZ 0.66 ± 0.31 1.31 ± 0.10** 1.29 ± 0.45** 
Striatum 0.35 ± 0.05 1.07 ± 0.06** 1.10 ± 0.15** 
Hippocampus 0.43 ± 0.06 -- 0.77 ± 0.01*** 
Olfactory Bulb 0.64 ± 0.2 -- 2.33 ± 1.86* 
Frontal Cortex 0.42 ± 0.15 1.79 ± 0.26** 1.13 ± 0.33** 
Choroid Plexus 0.57 ± 0.24 1.31 ± 0.23* 1.28 ± 0.44* 
Pituitary 0.93 ± 0.12 -- 4.15 ± 0.72*** 
Cerebellum 0.68 ± 0.16 -- 1.09 ± 0.97 
Other Tissue 0.33 ± 0.05 -- 0.75 ± 0.10** 
Lung 0.37 ± 0.13 -- 0.50 ± 0.01 
Femur 0.69 ± 0.10 1.68 ± 0.25** 2.40 ± 0.38** 
Plasma 0.004 ± 0.001 -- 0.010 ± 0.002** 
 
Table 6. Tissue Cu Concentrations Were Analyzed by Atomic Absorption 
Spectroscopy Following Intranasal Mn Exposure. Data represent mean ± S.D. µg/g; 
n=4-10; *p < 0.05, **p < 0.01when compared with controls. 
 
Cu Levels 
Tissue control 0.2 mg/kg 0.8 mg/kg 
SVZ 9.64 ± 2.81 5.17 ± 0.78** 1.28 ± 0.04** 
Striatum 2.57 ± 0.35 2.51 ± 0.59 4.98 ± 0.56** 
Hippocampus 2.81 ± 0.56 -- 2.33 ± 0.19 
Olfactory Bulb 2.34 ± 0.28 -- 2.64 ± 0.44 
Frontal Cortex 2.68 ± 0.31 2.39 ± 0.19 2.53 ± 0.22 
Choroid Plexus 3.34 ± 2.95 3.06 ± 0.75 2.54 ± 0.44 
Pituitary 0.54 ± 0.14 -- 0.45 ± 0.03 
Cerebellum 0.56 ± 0.4 -- 0.56 ± 0.06 
Other Tissue 0.21 ± 0.05 -- 0.24 ± 0.01 
Lung 0.50 ± 0.02 -- 0.51 ± 0.02 
Femur 0.59 ± 0.19 0.64 ± 0.09 0.67 ± 0.11 







4.4.3 Immunohistological Findings from Triple Labeled Brain Slices 
 In control animals, low magnification (x40) confocal images of sagittal brain 
sections revealed the fluorescent BrdU signal was localized to the lateral walls in the 
lateral ventricles where the SVZ is located (Figure 20). The BrdU signal can also be 
observed in the delta SVZ (ΔSVZ) region, located at the superior aspect of the SVZ 
where the RMS begins, and anteriorly into the RMS as well. At this low magnification, 
labeling for DCX and GFAP was also visible. This region shows high levels of DCX 
expression.  
As intranasal instillation of Mn significantly alters Mn and Cu levels in the SVZ, 
we hypothesized that Mn exposure would inhibit neurogenesis in the SVZ and ΔSVZ, the 
superior aspect of the SVZ leading directly to the RMS. To test this hypothesis, animals 
received twice daily injections of 50 mg/kg BrdU during the last four days of Mn 
exposure to pulse-label actively dividing cells in the SVZ. In contradiction to our original 
hypothesis, BrdU signals were clearly increased following Mn exposure (Figure 20 top 
row). Quantification of the average fluorescence intensity confirms the signal was 
significantly increased by 25.1% after 0.2 mg/kg Mn exposure (p < 0.05; Figure 21).  
An increase in BrdU signal indicates an increase in the proliferation of new cells 
in this neurogenic niche. These cells are capable of differentiating to neuroblasts or 
producing new glial cells to maintain the pool of astrocytic stem cells (ASCs), the true 
neural stem cells in the region. For a complete understanding of Mn-induced 
neurotoxicity, it is necessary to understand how Mn exposure affects these differentiation 
processes, potentially resulting in altered neuronal and glial populations. To test the 




group were triple-labeled for BrdU, DCX (to identify neuroblasts), and GFAP (to identify 
ASCs). Triple-labeling revealed that BrdU expressing cells in the SVZ also expressed 
DCX or GFAP, indicating that both neuroblasts and ASCs were actively proliferating in 
the SVZ. Quantification of the dual-fluorescence signals in sagittal slices revealed 
significant 27.0% increases in expression of both DCX and GFAP (p < 0.01) following 
0.2 mg/kg Mn exposure (Figure 21). These same changes were not observed following 
0.8 mg/kg Mn exposure. This indicated that Mn exposure not only increased the 
proliferation of cells, but also differentiation of the cells to either neuroblasts (DCX+) or 
ASCs (GFAP+).  
In the ΔSVZ region, DCX was significantly increased following 0.8 mg/kg Mn 
exposure (58.8%; p < 0.01). GFAP remained unchanged in the ΔSVZ region (p = 0.334). 
Combining the fluorescence intensities for the SVZ and ΔSVZ at low 
magnification (x40) revealed significant increases of 28.9%, 29.2%, and 8.9% for BrdU, 








Figure 20. Immunohistochemical triple labeling for BrdU, DCX, and GFAP in the 
SVZ at low magnification. Rats received twice daily injections of 50 mg/kg BrdU 
during the last four days of the study to pulse-label actively dividing cells in the SVZ. 
Representative images from each treatment group show labeling of BrdU (red), DCX 







Figure 21. Quantification of IHC triple labeling in the SVZ for BrdU, DCX, and 
GFAP at low magnification (x40). Bar graph shows the fluorescence intensity for each 





















 The trend in increasing expression of BrdU and DCX after Mn exposure observed 
at low magnification (x40) continued for the high magnification images (x100 and x400, 
Figure 22). At x100 magnification, BrdU label was significantly increased by 83.1%, and 
DCX label was significantly increased by 78.4% (p < 0.01) following 0.2 mg/kg Mn 
exposure. At x400 magnification, BrdU expression was significantly increased following 
both 0.2 and 0.8 mg/kg Mn exposure, 54.4% and 37.7%, respectively as compared with 
control (p < 0.01; Figure 23). Thus, Mn-exposure appeared to disturb the processes of 









Figure 22. Immunohistochemical triple labeling for BrdU, DCX, and GFAP in the 
SVZ at high magnification. Representative images from each treatment group are 
shown. The circle in the x100 magnification (top row) indicates the approximate area of 
the SVZ enlarged in the x400 magnification images below of BrdU (red), DCX (green), 






Figure 23. Quantification of IHC staining in the SVZ for BrdU, DCX, and GFAP at 
high magnification (x400). Bar graph showing fluorescence intensity for each label in 




















At higher magnification of the ΔSVZ region, we observed BrdU signal co-
localized with both the DCX and GFAP signals; this was particularly evident when 
comparing the BrdU/DCX and BrdU/GFAP combined images (Figure 24). 
Quantification of ΔSVZ images at high magnification (x100) similarly revealed a 53.5% 
significant increase in BrdU expression following 0.8 mg/kg Mn exposure (p < 0.05) 
(Figure 25). DCX and GFAP expression were non-significantly increased following Mn 
exposure (p = 0.08 and 0.06, respectively). Increasing magnification to x400 in the ΔSVZ 
showed significantly increased BrdU expression following both 0.2 and 0.8 mg/kg Mn 
exposure (71.7% and 74.6%, respectively) compared with controls (p < 0.05). 
Additionally, DCX expression significantly increased by 91.8% in the ΔSVZ following 









Figure 24. Immunohistochemical triple labeling for BrdU, DCX, and GFAP in the 
ΔSVZ at high magnification. Representative images from each treatment group are 
shown. The square in the x100 magnification (top row) indicates the approximate area of 
the ΔSVZ enlarged in the x400 magnification images below of BrdU (red), DCX (green), 








Figure 25. Quantification of IHC staining in the ΔSVZ region for BrdU, DCX, and 
GFAP at high magnification (x400). Bar graph showing fluorescence intensity for each 





















Newly proliferated BrdU+ cells may begin to migrate along the RMS to their final 
destination in the olfactory bulb. Cells that survive in the olfactory bulb are capable of 
migrating further to the glomerular layer or the granule layer. Therefore, we assessed the 
changes within these two layers of the olfactory bulb with or without Mn exposure. This 
examination is of particular importance in that intranasal manganese exposure resulted in 
the highest concentration of Mn in the olfactory bulb. High magnification images (x100) 
of the olfactory bulb (Figure 26) showed BrdU expression in the glomerular layer was 
significantly increased by 58.9% following 0.2 mg/kg intranasal Mn exposure (p < 0.01; 
Figure 27). Additionally within the glomerular layer, DCX expression was significantly 








Figure 26. Immunohistochemical triple labeling for BrdU, DCX, and GFAP in the 
olfactory bulb at high magnification (x100). Representative images from each 
treatment group are shown. The square indicates the glomerular cell layer of the olfactory 
bulb and the circle indicates the granule cell layer of the olfactory bulb labeled for BrdU 









Figure 27. Quantification of IHC staining in the olfactory bulb for BrdU, DCX, and 
GFAP at high magnification (x100). Bar graph showing the fluorescence intensity for 
each label in the granule and glomerular cell layers. Data represent mean ± S.D., n = 4; 





















4.4.4 Dmt1 and Ctr1 mRNA and Protein Expression Following Intranasal Mn Exposure 
 Altered metal levels in the brain have differential effects on brain function in 
neurodegenerative disease, and specifically in the SVZ, altered metal levels affect the 
processes of cell proliferation and differentiation critical for normal adult neurogenesis. A 
complete understanding of the factors affecting neurogenesis could potentially lead to 
improved therapies for neurodegenerative disease, stroke, and brain injury. Therefore, it 
is of utmost importance that we begin to explain the mechanisms responsible for altered 
metal homeostasis in the SVZ. Altered metal levels could be due to the changes in 
proteins participating in regulation of cellular metal homeostasis. Two metal transporters 
known to be involved in Mn and Cu homeostasis, i.e., divalent metal transporter-1 
(Dmt1) and Cu transporter 1 (Ctr1), were selected as candidates for further investigation. 
In previous studies, we have shown that Mn accumulation in the SVZ induces a 13% 
increase in Dmt1 following intraperitoneal exposure (Fu et al., 2015). However, 
following IN Mn exposure, qPCR results in this study revealed that neither Dmt1 nor 
Ctr1mRNA expression was significantly altered in SVZ, OB, STR, or HP (p values 
ranging from 0.28-0.67). Of note, increasing expression of Dmt1 in the STR was close to, 
but did not reach statistical significance (p = 0.07).  
By using Western blotting techniques, the total protein expression was also 
analyzed in these same tissues.  Although it appeared that CTR1 protein expression was 
increased in the SVZ, but decreased in the STR following Mn exposure, quantification of 
Western blots did not reveal significant differences between groups in all tissues 
examined. The most striking result from these studies was the discovery that there was 




  After intranasal Mn exposure, the highest levels of Mn in the brain were found in 
the OB. We investigated potential changes in α-synuclein and Iba1 in the OB following 
Mn exposure because some of the earliest symptoms of Parkinson’s disease are observed 
in this brain region. According to the Braak hypothesis of Parkinson’s disease pathology, 
olfactory structures are among the first to display pathological changes, and olfactory 
deficits are a common early symptom of Parkinson’s disease (Braak et al., 2003; 
Berendse et al., 2011). Additionally, increased α-synuclein aggregation is a hallmark 
Parkinson’s disease. Mn exposure is known to induce oxidative stress and inflammation 
which are important pathways in Mn-induced neurotoxicity; therefore, expression of 
Iba1, a marker of activated microglia, was analyzed in the olfactory bulb. Through these 
studies, it was revealed that olfactory α-synuclein was not significantly altered following 
IN Mn exposure (p = 0.22). Although it appeared Iba1 expression was significantly 
increased following Mn exposure, the increase did not reach statistical significance (p = 
0.06). Noticeably, the proteins in these blots were poorly resolved and the signals 
overlapped, particularly for the β-actin signal, which made them unsuitable for 
quantification. Although the quality of the Western Blot results leaves much to be 








Figure 28. Western blots showing CTR1, α-synuclein, and Iba1 protein expression 
following intranasal Mn exposure. CTR1 protein levels detected in SVZ (A), STR (B), 
HP (C), and OB (D) using horseradish peroxidase-linked secondary antibodies. α –
synuclein detected in OB (E), and Iba1 detected in OB (F) using Odyssey infrared 
imaging system. Each well contains approximately, 50 µg protein, n=3 per group. Each 





















4.4.5 HPLC Evaluation of Biogenic Amines in Olfactory Bulb and Thalamus 
These studies followed the dose regimen detailed by Blecharz-Klin et al. (2013) who 
investigated neurochemical alterations following the IN Mn exposure. These authors 
showed only modest changes in any neurotransmitter system with the most striking result 
being a significant decrease in DA concentrations in the hippocampus. They also showed 
a significant increase in norepinephrine in the cortex and a significant decrease in 
serotonin in the cortex, hippocampus and striatum. Magnetic resonance spectroscopy 
studies of the human population exposed to Mn consistently reveal group differences in 
GABA expression in the thalamus (Dydak et al, 2011). Blecharz-Klin et al. (2013) did 
not investigate changes in GABA, nor did they investigate changes in the thalamus. 
Therefore, in the present study, GABA concentrations in the thalamus and olfactory bulb 
were investigated using HPLC. Changes in monoamine levels, including dopamine and 
serotonin and their metabolites were also evaluated in these brain regions.  
Although the concentrations of GABA in the thalamus and OB were not significantly 
altered, it was interesting to note that thalamic GABA levels appeared to be reduced 
following Mn exposure (p = 0.32). Glutamate was not significantly altered in either the 
thalamus or olfactory bulb (p = 0.1-0.32). Lastly, monoamine data was not significantly 
altered following intranasal Mn exposure in either the OB or thalamus. DA 
concentrations in the thalamus appeared to be reduced following Mn exposure, but the 







Previous work from our lab has shown that Mn exposure following intraperitoneal 
injection leads to significant accumulation in the SVZ and significantly altered Cu levels 
in this region. Cu levels are normally high in the SVZ, an area with known neurogenic 
function, even in adulthood. We hypothesized that the high basal Cu concentrations in the 
SVZ were necessary for normal adult neurogenesis in this niche. The effects on adult 
neurogenesis resulting from altered metal homeostasis following intranasal Mn exposure 
were unknown in this area. The AAS data presented here demonstrated that intranasal 
instillation of Mn led to significant accumulation of Mn in the SVZ and correspondingly, 
a significant decrease in SVZ Cu concentrations was observed. The IHC data revealed a 
significant increase in the expression of BrdU in the SVZ, ΔSVZ, and glomerular cell 
layer of the olfactory bulb following intranasal Mn exposure. Additionally, expression of 
DCX in these regions was also significantly increased following Mn exposure. GFAP 
expression was significantly increased only in the SVZ, the finding was not surprising 
because GFAP labels astrocytic stem cells, the true stem cells of the SVZ niche. These 
cells do not migrate, but proliferate in the SVZ niche, maintaining a pool of 
undifferentiated progenitor cells. GFAP expression did not change in the ΔSVZ which 
could indicate that the superior aspect of the SVZ does not maintain a pool of neural stem 
cells. Recently, we showed BrdU+ cells mainly expressed DCX, with fewer BrdU+ cells 
expressing GFAP following intraperitoneal Mn exposure (Fu et al., 2015). Our similar 
findings here suggest that Mn exposure mainly affected proliferating neuroblasts 




The application of the intranasal instillation route of Mn exposure is novel to the 
study of adult neurogenesis. There are several advantages of intranasal instillation over 
other traditional exposure routes, including, but not limited to: a more biologically 
relevant dose route with greater bioavailability (Tjälve et al., 1996) following direct 
transport into the CNS (Dorman et al., 2004), smaller cumulative doses, and shorter study 
durations because Mn can bypass the blood-brain barrier (Thompson et al., 2007). 
Although neurochemistry was unaffected in the current study, modest changes in 
dopamine and serotonin and their metabolites have been observed following this dose 
administration (Blecharz-Klin et al., 2012). Additionally, we observed highly significant 
changes in both Mn and Cu concentrations in the brain following this route of exposure 
that are similar in magnitude to changes observed after intraperitoneal exposure. This is 
striking because the cumulative doses used in this study are less than 10% those used in 
intraperitoneal studies to achieve the same results. This finding suggests that Mn 
exposure by inhalation may be more harmful than other routes of exposure. Interestingly, 
changes in animals’ body weights and relative organ weights which are indicators of 
general toxicity (Oszlanczi et al., 2010) were not significantly different between 
intranasal and intraperitoneal exposures, suggesting that the intranasal route is no more 
toxic than is intraperitoneal exposure, with regard to systemic toxicity. 
After intranasal instillation, Mn levels were highest in the OB, suggesting Mn first 
entered the brain at the OB and followed retrograde transport to more posteriorly located 
brain structures, such as the SVZ and STR. Mn levels were unchanged at the cerebellum, 
which was anticipated given the expected rate of Mn transport. It is estimated to take 6 




whereas our study lasted for only two weeks. The same group of researchers has also 
shown that Mn concentrations in the OB remain elevated for up to 45 days following 
exposure (Dorman et al., 2004), suggesting there is great potential for Mn exposure to 
continue following dose cessation after this route of exposure.  
Because of the SVZ’s close proximity to the STR, it was important to confirm 
two discreet tissues were collected correctly at necropsy. Previous research from our lab 
has shown that tissue collected as SVZ shows amplification of nestin, a marker of 
proliferating cells following qPCR analysis. If this tissue was not the SVZ, there would 
be no amplification of this gene. Likewise, in the current study, Mn concentrations at 
each dose level were significantly different between the SVZ and the STR (control p < 
0.01, 0.2 mg/kg p < 0.001, and 0.8 mg/kg p < 0.05). Additionally, differences in the Cu 
concentrations following Mn exposure also verified that the SVZ and striatal tissues were 
distinct; Cu concentrations were significantly reduced in the SVZ, while they were 
significantly increased in the STR.    
Our observations raise several interesting questions: 1) what is the significance of the 
high Cu concentrations in the neurogenic niche; what is the function with regard to adult 
neurogenesis? 2) Are high Cu concentrations required for normal adult neurogenesis? 3) 
Is the mechanism responsible for accumulating high Cu levels in the SVZ altered 
following Mn exposure? 
We have shown that basal Cu levels are extraordinarily high in the SVZ and they 
significantly decreased following Mn exposure. Kikuchihara et al. (2015) also showed a 
significant reduction of Cu concentration in the subventricular zone (SGZ) following Mn 




those in surrounding tissues because we cannot dissect out the SGZ at this time. It is also 
unknown if Mn exposure affects the Cu level in the SGZ.  It would be possible in future 
studies to dissect out the entire dentate gyrus from the HP to check metal concentrations 
using AAS or use synchrotron analysis to detect Cu levels within the SGZ specifically. 
The results of the current study and the results from work in the SGZ by Kikuchihara’s 
group suggest that Cu homeostasis is important in adult neurogenesis (Kikuchihara et al., 
2015). Since a Cu imbalance is implicated in a variety of neurodegenerative diseases, it is 
possible that Cu dyshomeostasis is the beginning of a decline in proper brain repair 
mechanisms following Mn exposure. This deserves immediate investigation. Our results 










The transition metal Mn is the 12th most abundant element on earth (Nadaska et 
al., 2012). It is found in every cell in the body and is required for normal development 
and function of every cell in the body (Aschner et al., 2007; Crossgrove and Zheng, 2004; 
Guilarte, 2010). However, overexposure to this metal is toxic to various organ systems. 
The central nervous system is the primary target of Mn toxicity, with Mn accumulation in 
the globus pallidus producing signs and symptoms similar but not identical to idiopathic 
Parkinson’s disease, including bradykinesia, memory deficits, and kinetic tremor 
(Bowman et al., 2011; Jiang et al., 2006; Racette et al., 2005). Overexposure to Mn 
primarily results from inhalation of high concentrations of Mn in the air in occupational 
settings such as welding, smelting, and dry-battery production (Cowan et al., 2009a,b; 
Keen and Lönnerdal, 1995; Racette et al., 2012). Regulatory standards are designed to 
protect workers from toxic exposures; however, researchers studying these populations 
have routinely shown Mn exposures above regulatory standards occur. More alarming 
still is the fact that low-level occupational exposure, with air Mn concentrations at or 




and neuroendocrine changes may occur before structural damage occurs, and are 
linked to pathogenic conditions (Alessio et al., 1989; Cowan et al., 2009a,b; Dydak et al., 
2011; Lucchini and Zimmerman, 2009; Mutti et al., 1996). 
Research on Mn neurotoxicity has often investigated changes in neurotransmitter 
expression and function, and studies suggest that dopaminergic neurons and their 
terminals are lesioned similar to Parkinson’s disease following Mn exposure, but the 
results from other studies is often contradictory and the effect of Mn exposure on 
neurotransmitters remains uncertain.  
It is known that symptoms of Mn-induced toxicity continue to progress even 
though further exposure has stopped, but it is unknown whether release of Mn from 
storage organs including bone could account for continual disease progression.  
Lastly, it is unknown what the effect of Mn exposure is on the SVZ, a region with 
rich neurogenic potential; the SVZ in the lateral ventricles houses actively proliferating 
neural stem cells. These cells can differentiate and migrate anteriorly to the olfactory 
bulb. The olfactory bulb is the first brain region metals and other contaminants come into 
contact with following direct transport into the brain by way of olfactory neurons. The 
effect of olfactory Mn transport on either the olfactory bulb or the SVZ also remains 
unknown.  
The studies in this doctoral dissertation were designed to address several of these 





5.1.1 Chapter 2 Summary 
 Bone is a major storage organ for Mn, sequestering more than 40% of the total 
Mn in the body. The toxicokinetics of Mn in bone tissue, particularly the rate of 
accumulation, time to steady-state concentration, and half-life of Mn in bone remained 
unknown. Mn and Cu concentrations in bone tissues from rats orally exposed to Mn were 
evaluated at various times both during ongoing administration of Mn and following 
cessation of Mn exposure. We showed a rapid accumulation of Mn in bone followed by a 
much slower elimination from bone. We calculated the half-life of Mn in rat bone and for 
the first time were able to estimate the half-life of Mn in human bone to be approximately 
8.6 years. We showed that Mn reaches steady-state concentrations after only 6 weeks. 
Lastly, the results of our work showed that Mn concentrations in bone were well 
correlated with concentrations in brain, indicating that bone is an accurate biomarker of 
Mn exposure and Mn accumulation in brain. The significance of this work was 
immediately apparent—it has helped provide support for use of bone as a biomarker of 
Mn exposure in the human population.  
 
5.1.2 Chapter 3 Summary 
Motor symptoms resulting from Mn toxicity resemble idiopathic Parkinson’s 
disease. However, animal studies suggest that dopaminergic neurons selectively lesioned 
in Parkinson’s disease remain intact after Mn intoxication (Guilarte, 2010). Therefore, 
some other change must be responsible for behavioral observations and motor function.  




published (Gwiazda et al., 2007; Racette et al., 2012a), but the findings are often 
contradictory and widely debated. We investigated regional changes in dopamine and 
other neurotransmitters, including serotonin, norepinephrine, and GABA in rats 
subchronically exposed to Mn by intraperitoneal injection to attempt to explain 
differences in brain regions implicated in Parkinson’s disease. We also used three dose 
levels to uncover a possible dose-response relationship. We showed significantly 
increased levels of DA and its metabolites in the striatum, as well as increased dopamine 
turnover in other brain regions affected by Parkinson’s disease. Additionally, GABA 
levels were significantly higher in the hippocampus. No structural abnormalities were 
identifiable in any region evaluated. In conclusion, the results from this study showed 
that Mn exposure had more pronounced effects on neurotransmitter expression in the 
striatum rather than the substantia nigra following Mn exposure. We also showed that Mn 
exposure did have a dose-dependent effect on locomotor behavior in rats. 
 
5.1.3 Chapter 4 Summary 
 Excess exposure to Mn in the human population predominantly occurs following 
inhalation. Mn accumulates in the olfactory bulb and can be transported to deeper brain 
structures, possibly including the subventricular zone, an area with known neurogenic 
capacity. The effect of Mn exposure in this region was unknown. Following a two-week 
intranasal Mn exposure in rats and pulse-labeling of BrdU at the end of the study, brain 
sections were evaluated for changes in cell proliferation and differentiation in the SVZ. 




reduction in Cu concentrations in the SVZ following Mn exposure. This altered metal 
homeostasis was found to be coupled with altered cell proliferation and differentiation. 
Following Mn exposure, there were significantly more BrdU+ cells in the SVZ compared 
with controls. Additionally, there were more cells expressing markers for neuroblasts 
(DCX+) and astrocytic stem cells (GFAP+). Interestingly, we noted significantly 
increased expression of both BrdU and DCX, but not GFAP in the glomerular layer of the 
olfactory bulb. This is important because it shows for the first time that intranasal Mn 
exposure directly interacts with neurogenesis, potentially affecting neuronal repair 
mechanisms. 
5.2 Limitations 
 The studies in this dissertation have several limitations. First, the dose, exposure 
route and duration are different for each study. The method selected for each study design 
was appropriate, but the differences between studies limited the ability to directly 
compare the results. Therefore, it is difficult to draw conclusions between studies (i.e. 
between the studies of bone accumulation and neurogenesis).  Second, the sample sizes 
for neurochemistry and immunohistochemistry were limited. While the statistical power 
was sufficient to detect group differences, any important individual differences (for 
example cell death) may not have been captured. Lastly, changes in neurochemistry and 
neurogenesis due to Mn exposure are expected to be dynamic. The studies in this 
dissertation were designed to assess changes in these specific endpoints following Mn 
exposure. Because samples were collected at one point in time, in both cases 24 hr after 




perhaps neurochemistry is most significantly affected after the initial Mn exposure as 
opposed to 24 hr after cessation. It would have been beneficial to have collected samples 
at more than one point in time. Similarly, in studies of adult neurogenesis, without 
collecting samples over time, it is impossible to draw conclusions about how Mn 
exposure affects cell survival or migration. 
5.3 Future Directions 
The research in this dissertation has established that toxic Mn exposure can alter 
neurochemistry in regions important in neurodegenerative disease but there was no 
significant effect on dopaminergic cell loss. While our neurochemistry data from these 
studies did not result in any definitive dose-response relationship in neurotransmitter 
expression, we did show dose-dependent decrease in locomotor behaviors. The open field 
test may not be sensitive enough to detect the extent of behavioral changes resulting from 
Mn toxicity, nor does it allow for detecting changes in learning and memory following 
Mn exposure. Changes we observed in the hippocampus neurotransmission suggest 
changes in learning and memory following Mn exposure are possible and should be 
investigated. The Morris water maze is the common test used to determine differences in 
learning and memory and may be suitable here. To detect differences in motor function, 
the rotarod test coupled with a stride analysis test may be more suitable than the open 
field test. 
We have also showed that Mn exposure had significant effects on toxicokinetics 
of Mn storage in and elimination from bone. The levels of Mn in bone were significantly 




To facilitate development of bone as a suitable biomarker and development of a 
technique for measuring Mn in bone, it would be helpful to know the contribution of 
other tissues, including skin, muscle, and bone marrow, that could potentially interfere 
with collecting accurate measurements of a patient’s bone Mn concentrations. We have 
preliminary data suggesting neither muscle nor bone marrow contain substantial amounts 
of Mn, but this should be verified, and skin (including fur from animals) should be 
evaluated as well.  
Lastly, intranasal Mn exposure has been demonstrated to be an effective route of 
exposure for the study of Mn neurotoxicity and adult neurogenesis. The primary route of 
exposure in humans is by inhalation. By this route, a large percentage of Mn is taken into 
the CNS directly at the olfactory mucosa while a smaller fraction is inhaled or swallowed 
and passes into the blood. Circulation permits additional uptake of Mn into the CNS from 
the blood through the brain barrier systems. The method of intranasally instilling Mn 
directly at the olfactory mucosa maximizes the amount of Mn directly entering the CNS 
and minimizes the amount of Mn available to enter into systemic circulation.  
Mn accumulation in other brain regions leads to altered neurochemistry. Changes in 
neurochemistry may cause subtle neuronal injuries. It is worthwhile to investigate 
changes in neurochemistry in the SVZ and see if these subtle changes may trigger adult 
neurogenesis processes in the SVZ, leading to increased proliferation and migration of 
DCX+ cells to the OB for the purpose of neuronal repair. Additionally, it would be 
interesting to investigate levels of glutamate in the frontal cortex of intranasally instilled 
animals as changes in frontal cortex glutamate have been seen in MRS experiments with 




The answers to the following questions are currently unknown: 1) why are basal Cu 
levels are so high in the SVZ, 2) how does Mn accumulate in this region, and 3) how 
does Mn accumulation subsequently disrupt Cu homeostasis in the SVZ. It is important 
for a complete understanding of Mn neurotoxicity in relationship to neurodegenerative 
disease pathology that each of these questions be addressed. The present studies began to 
address how Mn accumulates and how Cu levels are altered following Mn exposure, but 
the results were inconclusive and the methods did not consider all possible transporters 
which could be participating in altered metal homeostasis. An analysis of the repertoire of 
metal transporters involved in Mn and Cu homeostasis should be undertaken to fully 
explain these changes.  
Overall, it can be concluded from the data presented in these studies that neurotoxic 
Mn exposure causes subclinical alterations in neurochemistry, metal concentrations and 
homeostasis, and animal behavior. These changes have not led to any detectable 
structural damage within the time frame investigated in these studies and the results of 
this work do not suggest that structural damage is imminent. However, some of the 
changes observed are themselves toxic (i.e., increased levels of DA), and are capable of 
affecting other biological processes. Therefore, it seems likely that Mn exposure may 
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